{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:37:08Z","timestamp":1792431428714,"version":"4.5.0"},"reference-count":333,"publisher":"Bentham Science Publishers Ltd.","issue":"15","funder":[{"DOI":"10.13039\/501100010739","name":"University of Camerino","doi-asserted-by":"publisher","award":["FAR 2011\/12 STI000044"],"award-info":[{"award-number":["FAR 2011\/12 STI000044"]}],"id":[{"id":"10.13039\/501100010739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010739","name":"University of Camerino","doi-asserted-by":"publisher","award":["FAR 2014\/15 FPI000044"],"award-info":[{"award-number":["FAR 2014\/15 FPI000044"]}],"id":[{"id":"10.13039\/501100010739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministry of Education, Universities and Research","doi-asserted-by":"publisher","award":["20094BJ9R7"],"award-info":[{"award-number":["20094BJ9R7"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministry of Education, Universities and Research","doi-asserted-by":"publisher","award":["2017CBNCYT_005"],"award-info":[{"award-number":["2017CBNCYT_005"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,6,2]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Histone Deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, and cell cycle arrest in cancer cells. Recently, their use has been clinically validated in cancer patients resulting in the approval by the FDA of four HDAC inhibitors, vorinostat, romidepsin, belinostat and panobinostat, used for the treatment of cutaneous\/peripheral T-cell lymphoma and multiple myeloma. Many more HDAC inhibitors are at different stages of clinical development for the treatment of hematological malignancies as well as solid tumors. Also, clinical trials of several HDAC inhibitors for use as anti-cancer drugs (alone or in combination with other anti-cancer therapeutics) are ongoing. In the intensifying efforts to discover new, hopefully, more therapeutically efficacious HDAC inhibitors, molecular modelingbased rational drug design has played an important role. In this review, we summarize four major structural classes of HDAC inhibitors (hydroxamic acid derivatives, aminobenzamide, cyclic peptide and short-chain fatty acids) that are in clinical trials and different computer modeling tools available for their structural modifications as a guide to discover additional HDAC inhibitors with greater therapeutic utility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0929867325666181016163110","type":"journal-article","created":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T04:09:55Z","timestamp":1539835795000},"page":"2449-2493","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents"],"prefix":"10.2174","volume":"27","author":[{"given":"Loredana","family":"Cappellacci","sequence":"first","affiliation":[{"name":"School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego R.","family":"Perinelli","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Maggi","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Grifantini","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Petrelli","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"Minucci S.","year":"2006","unstructured":"Minucci S.; Pelicci P.G.; Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006,6(1),38-51","journal-title":"Nat Rev Cancer"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"Bolden J.E.","year":"2006","unstructured":"Bolden J.E.; Peart M.J.; Johnstone R.W.; Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006,5(9),769-784","journal-title":"Nat Rev Drug Discov"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.canlet.2008.10.047","volume":"280","author":"Weichert W.","year":"2009","unstructured":"Weichert W.; HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009,280(2),168-176","journal-title":"Cancer Lett"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"6561","DOI":"10.1073\/pnas.1204429109","volume":"109","author":"Gammoh N.","year":"2012","unstructured":"Gammoh N.; Lam D.; Puente C.; Ganley I.; Marks P.A.; Jiang X.; Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci USA 2012,109(17),6561-6565","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/icb.2011.100","volume":"90","author":"Khan O.","year":"2012","unstructured":"Khan O.; La Thangue N.B.; HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012,90(1),85-94","journal-title":"Immunol Cell Biol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd4360","volume":"13","author":"Falkenberg K.J.","year":"2014","unstructured":"Falkenberg K.J.; Johnstone R.W.; Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014,13(9),673-691","journal-title":"Nat Rev Drug Discov"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","volume":"5","author":"Dokmanovic M.","year":"2007","unstructured":"Dokmanovic M.; Clarke C.; Marks P.A.; Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007,5(10),981-989","journal-title":"Mol Cancer Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.2174\/092986708783885282","volume":"15","author":"Chen L.","year":"2008","unstructured":"Chen L.; Petrelli R.; Felczak K.; Gao G.; Bonnac L.; Yu J.S.; Bennett E.M.; Pankiewicz K.W.; Nicotinamide adenine dinucleotide based therapeutics. Curr Med Chem 2008,15(7),650-670","journal-title":"Curr Med Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev.pharmtox.45.120403.095825","volume":"45","author":"Drummond D.C.","year":"2005","unstructured":"Drummond D.C.; Noble C.O.; Kirpotin D.B.; Guo Z.; Scott G.K.; Benz C.C.; Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005,45,495-528","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/ijc.22751","volume":"121","author":"Beckers T.","year":"2007","unstructured":"Beckers T.; Burkhardt C.; Wieland H.; Gimmnich P.; Ciossek T.; Maier T.; Sanders K.; Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 2007,121(5),1138-1148","journal-title":"Int J Cancer"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1124\/mol.105.014167","volume":"68","author":"Acharya M.R.","year":"2005","unstructured":"Acharya M.R.; Sparreboom A.; Venitz J.; Figg W.D.; Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 2005,68(4),917-932","journal-title":"Mol Pharmacol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nbt1272","volume":"25","author":"Marks P.A.","year":"2007","unstructured":"Marks P.A.; Breslow R.; Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007,25(1),84-90","journal-title":"Nat Biotechnol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4155\/fmc.12.3","volume":"4","author":"Gryder B.E.","year":"2012","unstructured":"Gryder B.E.; Sodji Q.H.; Oyelere A.K.; Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 2012,4(4),505-524","journal-title":"Future Med Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","volume":"14","author":"Steele N.L.","year":"2008","unstructured":"Steele N.L.; Plumb J.A.; Vidal L.; Tj\u00f8rnelund J.; Knoblauch P.; Rasmussen A.; Ooi C.E.; Buhl-Jensen P.; Brown R.; Evans T.R.; DeBono J.S.; A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008,14(3),804-810","journal-title":"Clin Cancer Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1358\/dof.2007.032.04.1094476","volume":"32","author":"Revill P.","year":"2007","unstructured":"Revill P.; Mealy N.; Serradell N.; Bolos J.; Rosa E.; Panobinostat. Drugs Future 2007,32,315-322","journal-title":"Drugs Future"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/abr.abr_142_19","volume":"8","author":"Sanaei M.","year":"2019","unstructured":"Sanaei M.; Kavoosi F.; Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers. Adv Biomed Res 2019,8,63","journal-title":"Adv Biomed Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1042\/bj20021321","volume":"370","author":"de Ruijter A.J.","year":"2003","unstructured":"de Ruijter A.J.; van Gennip A.H.; Caron H.N.; Kemp S.; van Kuilenburg A.B.; Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003,370(Pt 3),737-749","journal-title":"Biochem J"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","volume":"338","author":"Gregoretti I.V.","year":"2004","unstructured":"Gregoretti I.V.; Lee Y.M.; Goodson H.V.; Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004,338(1),17-31","journal-title":"J Mol Biol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1574-6976.2007.00100.x","volume":"32","author":"Brosch G.","year":"2008","unstructured":"Brosch G.; Loidl P.; Graessle S.; Histone modifications and chromatin dynamics: a focus on filamentous fungi. FEMS Microbiol Rev 2008,32(3),409-439","journal-title":"FEMS Microbiol Rev"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1128\/MCB.25.8.2873-2884.2005","volume":"25","author":"Yang X.J.","year":"2005","unstructured":"Yang X.J.; Gr\u00e9goire S.; Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol 2005,25(8),2873-2884","journal-title":"Mol Cell Biol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1139\/o01-116","volume":"79","author":"Fischle W.","year":"2001","unstructured":"Fischle W.; Kiermer V.; Dequiedt F.; Verdin E.; The emerging role of class II histone deacetylases. Biochem Cell Biol 2001,79(3),337-348","journal-title":"Biochem Cell Biol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nrm2346","volume":"9","author":"Yang X.J.","year":"2008","unstructured":"Yang X.J.; Seto E.; The Rpd3\/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008,9(3),206-218","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jss.2010.12.035","volume":"174","author":"Lian Z.R.","year":"2012","unstructured":"Lian Z.R.; Xu Y.F.; Wang X.B.; Gong J.P.; Liu Z.J.; Suppression of histone deacetylase 11 promotes expression of IL-10 in Kupffer cells and induces tolerance following orthotopic liver transplantation in rats. J Surg Res 2012,174(2),359-368","journal-title":"J Surg Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/ni.1673","volume":"10","author":"Villagra A.","year":"2009","unstructured":"Villagra A.; Cheng F.; Wang H.W.; Suarez I.; Glozak M.; Maurin M.; Nguyen D.; Wright K.L.; Atadja P.W.; Bhalla K.; Pinilla-Ibarz J.; Seto E.; Sotomayor E.M.; The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 2009,10(1),92-100","journal-title":"Nat Immunol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1182\/blood-2010-08-303701","volume":"117","author":"Buglio D.","year":"2011","unstructured":"Buglio D.; Khaskhely N.M.; Voo K.S.; Martinez-Valdez H.; Liu Y.J.; Younes A.; HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood 2011,117(10),2910-2917","journal-title":"Blood"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"11446","DOI":"10.1074\/jbc.M809394200","volume":"284","author":"Glozak M.A.","year":"2009","unstructured":"Glozak M.A.; Seto E.; Acetylation\/deacetylation modulates the stability of DNA replication licensing factor Cdt1. J Biol Chem 2009,284(17),11446-11453","journal-title":"J Biol Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1006\/bbrc.2000.3000","volume":"273","author":"Frye R.A.","year":"2000","unstructured":"Frye R.A.; Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 2000,273(2),793-798","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/gb-2004-5-5-224","volume":"5","author":"North B.J.","year":"2004","unstructured":"North B.J.; Verdin E.; Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol 2004,5(5),224","journal-title":"Genome Biol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1006\/bbrc.1999.0897","volume":"260","author":"Frye R.A.","year":"1999","unstructured":"Frye R.A.; Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 1999,260(1),273-279","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20070140","volume":"404","author":"Michan S.","year":"2007","unstructured":"Michan S.; Sinclair D.; Sirtuins in mammals: insights into their biological function. Biochem J 2007,404(1),1-13","journal-title":"Biochem J"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.molcel.2005.02.022","volume":"17","author":"Avalos J.L.","year":"2005","unstructured":"Avalos J.L.; Bever K.M.; Wolberger C.; Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol Cell 2005,17(6),855-868","journal-title":"Mol Cell"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4155\/fmc.14.44","volume":"6","author":"Hu J.","year":"2014","unstructured":"Hu J.; Jing H.; Lin H.; Sirtuin inhibitors as anticancer agents. Future Med Chem 2014,6(8),945-966","journal-title":"Future Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"7349","DOI":"10.1021\/acs.jmedchem.5b00719","volume":"58","author":"Bockman M.R.","year":"2015","unstructured":"Bockman M.R.; Kalinda A.S.; Petrelli R.; De la Mora-Rey T.; Tiwari D.; Liu F.; Dawadi S.; Nandakumar M.; Rhee K.Y.; Schnappinger D.; Finzel B.C.; Aldrich C.C.; Targeting Mycobacterium tuberculosis Biotin Protein Ligase (MtBPL) with Nucleoside-Based Bisubstrate Adenylation Inhibitors. J Med Chem 2015,58(18),7349-7369","journal-title":"J Med Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.2174\/0929867322666150821100720","volume":"22","author":"Pankiewicz K.W.","year":"2015","unstructured":"Pankiewicz K.W.; Petrelli R.; Singh R.; Felczak K.; Nicotinamide Adenine Dinucleotide Based Therapeutics, Update. Curr Med Chem 2015,22(34),3991-4028","journal-title":"Curr Med Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"20295","DOI":"10.3390\/molecules191220295","volume":"19","author":"Kozako T.","year":"2014","unstructured":"Kozako T.; Suzuki T.; Yoshimitsu M.; Arima N.; Honda S.; Soeda S.; Anticancer agents targeted to sirtuins. Molecules 2014,19(12),20295-20313","journal-title":"Molecules"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2174\/138161209787185742","volume":"15","author":"Borradaile N.M.","year":"2009","unstructured":"Borradaile N.M.; Pickering J.G.; NAD(, sirtuins, and cardiovascular disease. Curr Pharm Des 2009,15(1),110-117","journal-title":"Curr Pharm Des"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1474-4422(11)70013-8","volume":"10","author":"Bonda D.J.","year":"2011","unstructured":"Bonda D.J.; Lee H.G.; Camins A.; Pall\u00e0s M.; Casadesus G.; Smith M.A.; Zhu X.; The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurol 2011,10(3),275-279","journal-title":"Lancet Neurol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrm3293","volume":"13","author":"Houtkooper R.H.","year":"2012","unstructured":"Houtkooper R.H.; Pirinen E.; Auwerx J.; Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 2012,13(4),225-238","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/ng1531","volume":"37","author":"Fraga M.F.","year":"2005","unstructured":"Fraga M.F.; Ballestar E.; Villar-Garea A.; Boix-Chornet M.; Espada J.; Schotta G.; Bonaldi T.; Haydon C.; Ropero S.; Petrie K.; Iyer N.G.; P\u00e9rez-Rosado A.; Calvo E.; Lopez J.A.; Cano A.; Calasanz M.J.; Colomer D.; Piris M.A.; Ahn N.; Imhof A.; Caldas C.; Jenuwein T.; Esteller M.; Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005,37(4),391-400","journal-title":"Nat Genet"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17460441.2020.1736032","author":"Hamze A.","year":"2020","unstructured":"Hamze A.; How do we improve histone deacetylase inhibitor drug discovery? Expert Opin Drug Discov 2020,1-3","journal-title":"Expert Opin Drug Discov"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-3-642-21631-2_3","volume":"206","author":"Peng L.","year":"2011","unstructured":"Peng L.; Seto E.; Deacetylation of nonhistone proteins by HDACs and the implications in cancer. Handb Exp Pharmacol 2011,206,39-56","journal-title":"Handb Exp Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1586\/era.10.62","volume":"10","author":"Singh B.N.","year":"2010","unstructured":"Singh B.N.; Zhang G.; Hwa Y.L.; Li J.; Dowdy S.C.; Jiang S.W.; Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 2010,10(6),935-954","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref=43","first-page":"166","volume":"3","author":"Kim H.J.","year":"2011","unstructured":"Kim H.J.; Bae S.C.; Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 2011,3(2),166-179","journal-title":"Am J Transl Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"Mann B.S.","year":"2007","unstructured":"Mann B.S.; Johnson J.R.; Cohen M.H.; Justice R.; Pazdur R.; FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007,12(10),1247-1252","journal-title":"Oncologist"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","volume":"27","author":"Piekarz R.L.","year":"2009","unstructured":"Piekarz R.L.; Frye R.; Turner M.; Wright J.J.; Allen S.L.; Kirschbaum M.H.; Zain J.; Prince H.M.; Leonard J.P.; Geskin L.J.; Reeder C.; Joske D.; Figg W.D.; Gardner E.R.; Steinberg S.M.; Jaffe E.S.; Stetler-Stevenson M.; Lade S.; Fojo A.T.; Bates S.E.; Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009,27(32),5410-5417","journal-title":"J Clin Oncol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","volume":"28","author":"Whittaker S.J.","year":"2010","unstructured":"Whittaker S.J.; Demierre M.F.; Kim E.J.; Rook A.H.; Lerner A.; Duvic M.; Scarisbrick J.; Reddy S.; Robak T.; Becker J.C.; Samtsov A.; McCulloch W.; Kim Y.H.; Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010,28(29),4485-4491","journal-title":"J Clin Oncol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.13222","volume":"168","author":"Foss F.","year":"2015","unstructured":"Foss F.; Advani R.; Duvic M.; Hymes K.B.; Intragumtornchai T.; Lekhakula A.; Shpilberg O.; Lerner A.; Belt R.J.; Jacobsen E.D.; Laurent G.; Ben-Yehuda D.; Beylot-Barry M.; Hillen U.; Knoblauch P.; Bhat G.; Chawla S.; Allen L.F.; Pohlman B.; A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol 2015,168(6),811-819","journal-title":"Br J Haematol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"301","DOI":"10.7164\/antibiotics.47.301","volume":"47","author":"Ueda H.","year":"1994","unstructured":"Ueda H.; Nakajima H.; Hori Y.; Fujita T.; Nishimura M.; Goto T.; Okuhara M.; FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994,47(3),301-310","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","volume":"21","author":"Lee H.Z.","year":"2015","unstructured":"Lee H.Z.; Kwitkowski V.E.; Del Valle P.L.; Ricci M.S.; Saber H.; Habtemariam B.A.; Bullock J.; Bloomquist E.; Li Shen Y.; Chen X.H.; Brown J.; Mehrotra N.; Dorff S.; Charlab R.; Kane R.C.; Kaminskas E.; Justice R.; Farrell A.T.; Pazdur R.Y.; FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma. Clin Cancer Res Chen, X.H.; Brown, J.; Mehrotra, N.; Dorff, S.; Charlab, R.; Kane, R.C.; Kaminskas, E.; Justice, R.; Farrell, A.T.; Pazdur, R. 2015,21(12),2666-2670","journal-title":"Clin Cancer Res"},{"key":"ref=50","first-page":"34","volume":"3","author":"Kabel A.M.","year":"2015","unstructured":"Kabel A.M.; Baali F.H.; Histone deacetylase inhibitors: a hope for cancer patients. J Cancer Res Treat 2015,3,34-36","journal-title":"J Cancer Res Treat"},{"key":"ref=51","first-page":"84","volume":"9","author":"Raedler L.A.","year":"2016","unstructured":"Raedler L.A.; Farydak (Panobinostat): First HDAC inhibitor approved for patients with relapsed multiple myeloma. Am Health Drug Benefits 2016,9(Spec Feature),84-87","journal-title":"Am Health Drug Benefits"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"San-Miguel J.F.","year":"2014","unstructured":"San-Miguel J.F.; Hungria V.T.; Yoon S.S.; Beksac M.; Dimopoulos M.A.; Elghandour A.; Jedrzejczak W.W.; G\u00fcnther A.; Nakorn T.N.; Siritanaratkul N.; Corradini P.; Chuncharunee S.; Lee J-J.; Schlossman R.L.; Shelekhova T.; Yong K.; Tan D.; Numbenjapon T.; Cavenagh J.D.; Hou J.; LeBlanc R.; Nahi H.; Qiu L.; Salwender H.; Pulini S.; Moreau P.; Warzocha K.; White D.; Blad\u00e9 J.; Chen W.; de la Rubia J.; Gimsing P.; Lonial S.; Kaufman J.L.; Ocio E.M.; Veskovski L.; Sohn S.K.; Wang M.C.; Lee J.H.; Einsele H.; Sopala M.; Corrado C.; Bengoudifa B.R.; Binlich F.; Richardson P.G.; Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014,15(11),1195-1206","journal-title":"Lancet Oncol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/sj.bjc.6603463","volume":"95","author":"Richon V.M.","year":"2006","unstructured":"Richon V.M.; Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 2006,95,S2-S6","journal-title":"Br J Cancer"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/1568026619666190122144949","volume":"19","author":"Li Y.","year":"2019","unstructured":"Li Y.; Wang F.; Chen X.; Wang J.; Zhao Y.; Li Y.; He B.; Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups. Curr Top Med Chem 2019,19(3),223-241","journal-title":"Curr Top Med Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-014-1433-2","volume":"118","author":"Shi W.","year":"2014","unstructured":"Shi W.; Lawrence Y.R.; Choy H.; Werner-Wasik M.; Andrews D.W.; Evans J.J.; Judy K.D.; Farrell C.J.; Moshel Y.; Berger A.C.; Bar-Ad V.; Dicker A.P.; Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial. J Neurooncol 2014,118(2),313-319","journal-title":"J Neurooncol"},{"key":"ref=56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024468","volume":"6","author":"Sarfstein R.","year":"2011","unstructured":"Sarfstein R.; Bruchim I.; Fishman A.; Werner H.; The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway. PLoS One 2011,6(9)","journal-title":"PLoS One"},{"key":"ref=57","first-page":"30","volume":"3","author":"M\u00e9ndez M.","year":"2011","unstructured":"M\u00e9ndez M.; Custodio A.; Provencio M.; New molecular targeted therapies for advanced non-small-cell lung cancer. J Thorac Dis 2011,3(1),30-56","journal-title":"J Thorac Dis"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1158\/1535-7163.MCT-12-0933","volume":"12","author":"Ma T.","year":"2013","unstructured":"Ma T.; Galimberti F.; Erkmen C.P.; Memoli V.; Chinyengetere F.; Sempere L.; Beumer J.H.; Anyang B.N.; Nugent W.; Johnstone D.; Tsongalis G.J.; Kurie J.M.; Li H.; Direnzo J.; Guo Y.; Freemantle S.J.; Dragnev K.H.; Dmitrovsky E.; Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. Mol Cancer Ther 2013,12(8),1545-1555","journal-title":"Mol Cancer Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/1748-717X-7-165","volume":"7","author":"Saelen M.G.","year":"2012","unstructured":"Saelen M.G.; Ree A.H.; Kristian A.; Fleten K.G.; Furre T.; Hektoen H.H.; Flatmark K.; Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. Radiat Oncol 2012,7,165","journal-title":"Radiat Oncol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/bjh.12326","volume":"162","author":"Oki Y.","year":"2013","unstructured":"Oki Y.; Younes A.; Copeland A.; Hagemeister F.; Fayad L.E.; McLaughlin P.; Shah J.; Fowler N.; Romaguera J.; Kwak L.W.; Pro B.; Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 2013,162(1),138-141","journal-title":"Br J Haematol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10147-011-0348-6","volume":"18","author":"Doi T.","year":"2013","unstructured":"Doi T.; Hamaguchi T.; Shirao K.; Chin K.; Hatake K.; Noguchi K.; Otsuki T.; Mehta A.; Ohtsu A.; Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. Int J Clin Oncol 2013,18(1),87-95","journal-title":"Int J Clin Oncol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","volume":"138","author":"McClure J.J.","year":"2018","unstructured":"McClure J.J.; Li X.; Chou C.J.; Advances and challenges of HDAC inhibitors in cancer therapeutics. Adv Cancer Res 2018,138,183-211","journal-title":"Adv Cancer Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","volume":"26","author":"Marks P.A.","year":"2007","unstructured":"Marks P.A.; Discovery and development of SAHA as an anticancer agent. Oncogene 2007,26(9),1351-1356","journal-title":"Oncogene"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","volume":"27","author":"Lane A.A.","year":"2009","unstructured":"Lane A.A.; Chabner B.A.; Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009,27(32),5459-5468","journal-title":"J Clin Oncol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","volume":"26","author":"Xu W.S.","year":"2007","unstructured":"Xu W.S.; Parmigiani R.B.; Marks P.A.; Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007,26(37),5541-5552","journal-title":"Oncogene"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.clml.2016.08.009","volume":"16","author":"Foss F.","year":"2016","unstructured":"Foss F.; Duvic M.; Lerner A.; Waksman J.; Whittaker S.; Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clin Lymphoma Myeloma Leuk 2016,16(11),637-643","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1080\/10428194.2017.1361022","volume":"59","author":"Duvic M.","year":"2018","unstructured":"Duvic M.; Bates S.E.; Piekarz R.; Eisch R.; Kim Y.H.; Lerner A.; Robak T.; Samtsov A.; Becker J.C.; McCulloch W.; Waksman J.; Whittaker S.; Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma 2018,59(4),880-887","journal-title":"Leuk Lymphoma"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bioorg.2016.05.005","volume":"67","author":"Manal M.","year":"2016","unstructured":"Manal M.; Chandrasekar M.J.; Gomathi Priya J.; Nanjan M.J.; Inhibitors of histone deacetylase as antitumor agents: A critical review. Bioorg Chem 2016,67,18-42","journal-title":"Bioorg Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"7237","DOI":"10.1021\/ja9613724","volume":"118","author":"Li K.W.","year":"1996","unstructured":"Li K.W.; Wu J.; Xing W.; Simon J.A.; Total synthesis of the antitumor depsipeptide FR-901,228. J Am Chem Soc 1996,118,7237-7248","journal-title":"J Am Chem Soc"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1006\/excr.1998.4027","volume":"241","author":"Nakajima H.","year":"1998","unstructured":"Nakajima H.; Kim Y.B.; Terano H.; Yoshida M.; Horinouchi S.; FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998,241(1),126-133","journal-title":"Exp Cell Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"311","DOI":"10.7164\/antibiotics.47.311","volume":"47","author":"Shigematsu N.","year":"1994","unstructured":"Shigematsu N.; Ueda H.; Takase S.; Tanaka H.; Yamamoto K.; Tada T.; FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination. J Antibiot (Tokyo) 1994,47(3),311-314","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"315","DOI":"10.7164\/antibiotics.47.315","volume":"47","author":"Ueda H.","year":"1994","unstructured":"Ueda H.; Manda T.; Matsumoto S.; Mukumoto S.; Nishigaki F.; Kawamura I.; Shimomura K.; FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994,47(3),315-323","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"Piekarz R.L.","year":"2011","unstructured":"Piekarz R.L.; Frye R.; Prince H.M.; Kirschbaum M.H.; Zain J.; Allen S.L.; Jaffe E.S.; Ling A.; Turner M.; Peer C.J.; Figg W.D.; Steinberg S.M.; Smith S.; Joske D.; Lewis I.; Hutchins L.; Craig M.; Fojo A.T.; Wright J.J.; Bates S.E.; Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011,117(22),5827-5834","journal-title":"Blood"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.biopha.2014.01.002","volume":"68","author":"Karthik S.","year":"2014","unstructured":"Karthik S.; Sankar R.; Varunkumar K.; Ravikumar V.; Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells. Biomed Pharmacother 2014,68(3),327-334","journal-title":"Biomed Pharmacother"},{"key":"ref=75","first-page":"219","volume":"10","author":"Robertson F.M.","year":"2013","unstructured":"Robertson F.M.; Chu K.; Boley K.M.; Ye Z.; Liu H.; Wright M.C.; Moraes R.; Zhang X.; Green T.L.; Barsky S.H.; Heise C.; Cristofanilli M.; The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis. J Exp Ther Oncol 2013,10(3),219-233","journal-title":"J Exp Ther Oncol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3109\/07357907.2012.675382","volume":"30","author":"Jones S.F.","year":"2012","unstructured":"Jones S.F.; Infante J.R.; Spigel D.R.; Peacock N.W.; Thompson D.S.; Greco F.A.; McCulloch W.; Burris H.A.; Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors. Cancer Invest 2012,30(6),481-486","journal-title":"Cancer Invest"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-13-0095","volume":"19","author":"Amiri-Kordestani L.","year":"2013","unstructured":"Amiri-Kordestani L.; Luchenko V.; Peer C.J.; Ghafourian K.; Reynolds J.; Draper D.; Frye R.; Woo S.; Venzon D.; Wright J.; Skarulis M.; Figg W.D.; Fojo T.; Bates S.E.; Piekarz R.L.; Phase I trial of a new schedule of romidepsin in patients with advanced cancers. Clin Cancer Res 2013,19(16),4499-4507","journal-title":"Clin Cancer Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"15s","DOI":"10.1200\/jco.2013.31.15_suppl.tps8616","volume":"31","author":"Delarue R.","year":"2013","unstructured":"Delarue R.; Zinzani P.L.; Hertzberg M.S.; Kim W.S.; Caballero D.; Pezzutto A.; Andre M.; Da Silva M.G.; Gaulard P.; Bertrand Coiffier B.; ROCHOP study: A phase III randomized study of CHOP compared to romidepsin-CHOP in untreated peripheral T-cell lymphoma. J Clin Oncol 2013,31,15s","journal-title":"J Clin Oncol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40265-014-0275-8","volume":"74","author":"Poole R.M.","year":"2014","unstructured":"Poole R.M.; Belinostat: first global approval. Drugs 2014,74(13),1543-1554","journal-title":"Drugs"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","volume":"29","author":"Giaccone G.","year":"2011","unstructured":"Giaccone G.; Rajan A.; Berman A.; Kelly R.J.; Szabo E.; LopezChavez, A.; Trepel, J.; Lee, M.J.; Cao, L.; Espinoza-Delgado, I.; Spittler, J.; Loehrer, P.J. Sr. Phase II study of belinostat in patients with recurrent or advanced thymic epithelial tumors. J Clin Oncol 2011,29,2052-2059","journal-title":"J Clin Oncol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.ejca.2010.02.047","volume":"46","author":"Mackay H.J.","year":"2010","unstructured":"Mackay H.J.; Hirte H.; Colgan T.; Covens A.; MacAlpine K.; Grenci P.; Wang L.; Mason J.; Pham P.A.; Tsao M.S.; Pan J.; Zwiebel J.; Oza A.M.; Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer 2010,46(9),1573-1579","journal-title":"Eur J Cancer"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ygyno.2012.02.019","volume":"125","author":"Dizon D.S.","year":"2012","unstructured":"Dizon D.S.; Blessing J.A.; Penson R.T.; Drake R.D.; Walker J.L.; Johnston C.M.; Disilvestro P.A.; Fader A.N.; A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012,125(2),367-371","journal-title":"Gynecol Oncol"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/IGC.0b013e31825736fd","volume":"22","author":"Dizon D.S.","year":"2012","unstructured":"Dizon D.S.; Damstrup L.; Finkler N.J.; Lassen U.; Celano P.; Glasspool R.; Crowley E.; Lichenstein H.S.; Knoblach P.; Penson R.T.; Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. Int J Gynecol Cancer 2012,22,979-986","journal-title":"Int J Gynecol Cancer"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00262-020-02537-4","volume":"69","author":"Battaglia A.","year":"2020","unstructured":"Battaglia A.; Buzzonetti A.; Fossati M.; Scambia G.; Fattorossi A.; Madiyalakan M.R.; Yolanda D.; Mahnke Y.D.; Nicodemus C.; Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin\/paclitaxel plus oregovomab in ovarian cancer patients. Cancer Immunol Immunother 2020,69,383-397","journal-title":"Cancer Immunol Immunother"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.3109\/10428194.2013.877134","volume":"55","author":"Kirschbaum M.H.","year":"2014","unstructured":"Kirschbaum M.H.; Foon K.A.; Frankel P.; Ruel C.; Pulone B.; Tuscano J.M.; Newman E.M.; A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 2014,55(10),2301-2304","journal-title":"Leuk Lymphoma"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-14-0968","volume":"20","author":"Thomas A.","year":"2014","unstructured":"Thomas A.; Rajan A.; Szabo E.; Tomita Y.; Carter C.A.; Scepura B.; Lopez-Chavez A.; Lee M.J.; Redon C.E.; Frosch A.; Peer C.J.; Chen Y.; Piekarz R.; Steinberg S.M.; Trepel J.B.; Figg W.D.; Schrump D.S.; Giaccone G.; A phase I\/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. Clin Cancer Res 2014,20(21),5392-5402","journal-title":"Clin Cancer Res"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10637-009-9219-7","volume":"28","author":"Ma B.B.","year":"2010","unstructured":"Ma B.B.; Sung F.; Tao Q.; Poon F.F.; Lui V.W.; Yeo W.; Chan S.L.; Chan A.T.; The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs 2010,28(2),107-114","journal-title":"Invest New Drugs"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1097\/CAD.0000000000000122","volume":"25","author":"Savickiene J.","year":"2014","unstructured":"Savickiene J.; Treigyte G.; Valiuliene G.; Stirblyte I.; Navakauskiene R.; Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells. Anticancer Drugs 2014,25(8),938-949","journal-title":"Anticancer Drugs"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1038\/nbt.1724","volume":"28","author":"Mack G.S.","year":"2010","unstructured":"Mack G.S.; To selectivity and beyond. Nat Biotechnol 2010,28(12),1259-1266","journal-title":"Nat Biotechnol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","volume":"49","author":"Duvic M.","year":"2013","unstructured":"Duvic M.; Dummer R.; Becker J.C.; Poulalhon N.; Ortiz Romero P.; Grazia Bernengo M.; Lebb\u00e9 C.; Assaf C.; Squier M.; Williams D.; Marshood M.; Tai F.; Prince H.M.; Panobinostat activity in both bexarotene-exposed and -na\u00efve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 2013,49(2),386-394","journal-title":"Eur J Cancer"},{"key":"ref=91","first-page":"33","volume":"3","author":"Prince H.M.","year":"2009","unstructured":"Prince H.M.; Bishton M.; Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T lymphoma. Hematol Meeting Rep 2009,3,33-38","journal-title":"Hematol Meeting Rep"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1007\/s10637-011-9666-9","volume":"30","author":"Fukutomi A.","year":"2012","unstructured":"Fukutomi A.; Hatake K.; Matsui K.; Sakajiri S.; Hirashima T.; Tanii H.; Kobayashi K.; Yamamoto N.; A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. Invest New Drugs 2012,30(3),1096-1106","journal-title":"Invest New Drugs"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","volume":"30","author":"Younes A.","year":"2012","unstructured":"Younes A.; Sureda A.; Ben-Yehuda D.; Zinzani P.L.; Ong T.C.; Prince H.M.; Harrison S.J.; Kirschbaum M.; Johnston P.; Gallagher J.; Le Corre C.; Shen A.; Engert A.; Panobinostat in patients with relapsed\/refractory Hodgkin\u2019s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012,30(18),2197-2203","journal-title":"J Clin Oncol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/leu.2013.325","volume":"28","author":"Platzbecker U.","year":"2014","unstructured":"Platzbecker U.; Al-Ali H.K.; Gattermann N.; Haase D.; Janzen V.; Krauter J.; G\u00f6tze K.; Schlenk R.; Nolte F.; Letsch A.; Ottmann O.G.; K\u00fcndgen A.; L\u00fcbbert M.; Germing U.; Wermke M.; Reinhard H.; Weiss C.; Lieder K.; Ehninger G.; Leismann O.; Giagounidis A.; Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients. Leukemia 2014,28(3),696-698","journal-title":"Leukemia"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/ajh.22198","volume":"87","author":"Dimicoli S.","year":"2012","unstructured":"Dimicoli S.; Jabbour E.; Borthakur G.; Kadia T.; Estrov Z.; Yang H.; Kelly M.; Pierce S.; Kantarjian H.; Garcia-Manero G.; Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol 2012,87(1),127-129","journal-title":"Am J Hematol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","volume":"21","author":"Laubach J.P.","year":"2015","unstructured":"Laubach J.P.; Moreau P.; San-Miguel J.F.; Richardson P.G.; Panobinostat for the treatment of multiple myeloma. Clin Cancer Res 2015,21(21),4767-4773","journal-title":"Clin Cancer Res"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/43710","volume":"401","author":"Finnin M.S.","year":"1999","unstructured":"Finnin M.S.; Donigian J.R.; Cohen A.; Richon V.M.; Rifkind R.A.; Marks P.A.; Breslow R.; Pavletich N.P.; Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999,401(6749),188-193","journal-title":"Nature"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0378-1119(95)00214-Q","volume":"160","author":"Yoshida S.","year":"1995","unstructured":"Yoshida S.; Ohya Y.; Hirose R.; Nakano A.; Anraku Y.; STT10, a novel class-D VPS yeast gene required for osmotic integrity related to the PKC1\/STT1 protein kinase pathway. Gene 1995,160(1),117-122","journal-title":"Gene"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.2174\/0929867043365099","volume":"11","author":"Vanhaecke T.","year":"2004","unstructured":"Vanhaecke T.; Papeleu P.; Elaut G.; Rogiers V.; Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem 2004,11(12),1629-1643","journal-title":"Curr Med Chem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1006\/excr.1994.1248","volume":"214","author":"Hoshikawa Y.","year":"1994","unstructured":"Hoshikawa Y.; Kwon H.J.; Yoshida M.; Horinouchi S.; Beppu T.; Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res 1994,214(1),189-197","journal-title":"Exp Cell Res"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0168-8278(01)00257-4","volume":"36","author":"Herold C.","year":"2002","unstructured":"Herold C.; Ganslmayer M.; Ocker M.; Hermann M.; Geerts A.; Hahn E.G.; Schuppan D.; The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 2002,36(2),233-240","journal-title":"J Hepatol"},{"key":"ref=102","first-page":"1181","volume":"1","author":"Strait K.A.","year":"2002","unstructured":"Strait K.A.; Dabbas B.; Hammond E.H.; Warnick C.T.; Iistrup S.J.; Ford C.D.; Ford C.D.; Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther 2002,1(13),1181-1190","journal-title":"Mol Cancer Ther"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/mc.10145","volume":"38","author":"Donadelli M.","year":"2003","unstructured":"Donadelli M.; Costanzo C.; Faggioli L.; Scupoli M.T.; Moore P.S.; Bassi C.; Scarpa A.; Palmieri M.; Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog 2003,38(2),59-69","journal-title":"Mol Carcinog"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3892\/ijo.22.5.1129","volume":"22","author":"Park W.H.","year":"2003","unstructured":"Park W.H.; Jung C.W.; Park J.O.; Kim K.; Kim W.S.; Im Y.H.; Lee M.H.; Kang W.K.; Park K.; Trichostatin inhibits the growth of ACHN renal cell carcinoma cells via cell cycle arrest in association with p27, or apoptosis. Int J Oncol 2003,22(5),1129-1134","journal-title":"Int J Oncol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1677\/joe.0.1790041","volume":"179","author":"Margueron R.","year":"2003","unstructured":"Margueron R.; Licznar A.; Lazennec G.; Vignon F.; Cavaill\u00e8s V.; Oestrogen receptor \u03b1 increases p21(WAF1\/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells. J Endocrinol 2003,179(1),41-53","journal-title":"J Endocrinol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","volume":"23","author":"Kelly W.K.","year":"2005","unstructured":"Kelly W.K.; O\u2019Connor O.A.; Krug L.M.; Chiao J.H.; Heaney M.; Curley T.; MacGregore-Cortelli B.; Tong W.; Secrist J.P.; Schwartz L.; Richardson S.; Chu E.; Olgac S.; Marks P.A.; Scher H.; Richon V.M.; Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005,23(17),3923-3931","journal-title":"J Clin Oncol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","volume":"24","author":"O\u2019Connor O.A.","year":"2006","unstructured":"O\u2019Connor O.A.; Heaney M.L.; Schwartz L.; Richardson S.; Willim R.; MacGregor-Cortelli B.; Curly T.; Moskowitz C.; Portlock C.; Horwitz S.; Zelenetz A.D.; Frankel S.; Richon V.; Marks P.; Kelly W.K.; Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006,24(1),166-173","journal-title":"J Clin Oncol"},{"key":"ref=108","first-page":"3578","volume":"9","author":"Kelly W.K.","year":"2003","unstructured":"Kelly W.K.; Richon V.M.; O\u2019Connor O.; Curley T.; MacGregor-Curtelli B.; Tong W.; Klang M.; Schwartz L.; Richardson S.; Rosa E.; Drobnjak M.; Cordon-Cordo C.; Chiao J.H.; Rifkind R.; Marks P.A.; Scher H.; Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003,9(10 Pt 1),3578-3588","journal-title":"Clin Cancer Res"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","volume":"109","author":"Duvic M.","year":"2007","unstructured":"Duvic M.; Talpur R.; Ni X.; Zhang C.; Hazarika P.; Kelly C.; Chiao J.H.; Reilly J.F.; Ricker J.L.; Richon V.M.; Frankel S.R.; Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007,109(1),31-39","journal-title":"Blood"},{"key":"ref=110","first-page":"3354","volume":"15","author":"Bhalla S.","year":"2009","unstructured":"Bhalla S.; Balasubramanian S.; David D.; Sirisawad M.; Joseph Buggy J.; Mauro L.; Prachand S.; Miller R.; Gordon L.I.; Andrew M.; Evens A.M.; The histone deacetylase inhibitor PCI-24781 induces caspase and ROS-dependent apoptosis through NF-kB and is synergistic with Bortezomib in lymphoma cells. Cancer Res 2009,15,3354-3365","journal-title":"Cancer Res"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10637-015-0206-x","volume":"33","author":"Morschhauser F.","year":"2015","unstructured":"Morschhauser F.; Terriou L.; Coiffier B.; Bachy E.; Varga A.; Kloos I.; Leli\u00e8vre H.; Sarry A.L.; Depil S.; Ribrag V.; Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs 2015,33(2),423-431","journal-title":"Invest New Drugs"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3324\/haematol.2016.154377","volume":"102","author":"Ribrag V.","year":"2017","unstructured":"Ribrag V.; Kim W.S.; Bouabdallah R.; Lim S.T.; Coiffier B.; Illes A.; Lemieux B.; Dyer M.J.S.; Offner F.; Felloussi Z.; Kloos I.; Luan Y.; Vezan R.; Graef T.; Morschhauser F.; Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. Haematologica 2017,102(5),903-909","journal-title":"Haematologica"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1158\/1078-0432.CCR-15-0624","volume":"22","author":"Evens A.M.","year":"2016","unstructured":"Evens A.M.; Balasubramanian S.; Vose J.M.; Harb W.; Gordon L.I.; Langdon R.; Sprague J.; Sirisawad M.; Mani C.; Yue J.; Luan Y.; Horton S.; Graef T.; Bartlett N.L.; A Phase I\/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed\/refractory lymphoma. Clin Cancer Res 2016,22,1060-1068","journal-title":"Clin Cancer Res"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/1120009X.2016.1145375","volume":"28","author":"Ganai S.A.","year":"2016","unstructured":"Ganai S.A.; Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies. J Chemother 2016,28(4),247-254","journal-title":"J Chemother"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","volume":"150","author":"Rambaldi A.","year":"2010","unstructured":"Rambaldi A.; Dellacasa C.M.; Finazzi G.; Carobbio A.; Ferrari M.L.; Guglielmelli P.; Gattoni E.; Salmoiraghi S.; Finazzi M.C.; Di Tollo S.; D\u2019Urzo C.; Vannucchi A.M.; Barosi G.; Barbui T.; A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010,150(4),446-455","journal-title":"Br J Haematol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2119\/molmed.2011.00020","volume":"17","author":"Furlan A.","year":"2011","unstructured":"Furlan A.; Monzani V.; Reznikov L.L.; Leoni F.; Fossati G.; Modena D.; Mascagni P.; Dinarello C.A.; Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol Med 2011,17(5-6),353-362","journal-title":"Mol Med"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/bjh.12332","volume":"161","author":"Finazzi G.","year":"2013","unstructured":"Finazzi G.; Vannucchi A.M.; Martinelli V.; Ruggeri M.; Nobile F.; Specchia G.; Pogliani E.M.; Olimpieri O.M.; Fioritoni G.; Musolino C.; Cilloni D.; Sivera P.; Barosi G.; Finazzi M.C.; Di Tollo S.; Demuth T.; Barbui T.; Rambaldi A.; A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br J Haematol 2013,161(5),688-694","journal-title":"Br J Haematol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"9891","DOI":"10.1021\/jm301098e","volume":"55","author":"Bergman J.A.","year":"2012","unstructured":"Bergman J.A.; Woan K.; Perez-Villarroel P.; Villagra A.; Sotomayor E.M.; Kozikowski A.P.; Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem 2012,55(22),9891-9899","journal-title":"J Med Chem"},{"key":"ref=119","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.14","volume":"2","author":"Novotny-Diermayr V.","year":"2012","unstructured":"Novotny-Diermayr V.; Hart S.; Goh K.C.; Cheong A.; Ong L-C.; Hentze H.; Pasha M.K.; Jayaraman R.; Ethirajulu K.; Wood J.M.; The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J 2012,2(5)","journal-title":"Blood Cancer J"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/cncr.30533","volume":"123","author":"Garcia-Manero G.","year":"2017","unstructured":"Garcia-Manero G.; Montalban-Bravo G.; Berdeja J.G.; Abaza Y.; Jabbour E.; Essell J.; Lyons R.M.; Ravandi F.; Maris M.; Heller B.; DeZern A.E.; Babu S.; Wright D.; Anz B.; Boccia R.; Komrokji R.S.; Kuriakose P.; Reeves J.; Sekeres M.A.; Kantarjian H.M.; Ghalie R.; Roboz G.J.; Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer 2017,123(6),994-1002","journal-title":"Cancer"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/pbc.24694","volume":"60","author":"Zorzi A.P.","year":"2013","unstructured":"Zorzi A.P.; Bernstein M.; Samson Y.; Wall D.A.; Desai S.; Nicksy D.; Wainman N.; Eisenhauer E.; Baruchel S.; A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program\/C17 pediatric phase I consortium. Pediatr Blood Cancer 2013,60(11),1868-1874","journal-title":"Pediatr Blood Cancer"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1365-2141.2010.08124.x","volume":"149","author":"Mandl-Weber S.","year":"2010","unstructured":"Mandl-Weber S.; Meinel F.G.; Jankowsky R.; Oduncu F.; Schmidmaier R.; Baumann P.; The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol 2010,149(4),518-528","journal-title":"Br J Haematol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-13-0735","volume":"19","author":"Brunetto A.T.","year":"2013","unstructured":"Brunetto A.T.; Ang J.E.; Lal R.; Olmos D.; Molife L.R.; Kristeleit R.; Parker A.; Casamayor I.; Olaleye M.; Mais A.; Hauns B.; Strobel V.; Hentsch B.; de Bono J.S.; First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2013,19(19),5494-5504","journal-title":"Clin Cancer Res"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1182\/blood.V116.21.2811.2811","volume":"116","author":"Walewski J.","year":"2010","unstructured":"Walewski J.; Paszkiewicz-Kozik E.; Borsaru G.; Moicean A.; Warszewska A.; Strobel K.; Biggi A.; Hauns B.; Mais A.; Henning S.W.; Resminostat in Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the Saphire phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor. Blood 2010,116,2811","journal-title":"Blood"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1182\/blood.V118.21.2675.2675","volume":"118","author":"Walewski J.","year":"2011","unstructured":"Walewski J.; Paszkiewicz-Kozik E.; Warszewska A.; Borsaru G.; Moicean A.; Hellmann A.; Mayer J.; Hauns B.; Mais A.; Henning S.W.; Final results of the Phase II saphire trial of resminostat (4SC-201) in patients with relapsed\/refractory Hodgkin lymphoma. Blood 2011,118,2675","journal-title":"Blood"},{"key":"ref=126","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.e15088","author":"Bitzer M.","year":"2013","unstructured":"Bitzer M.; Ganten T.M.; Woerns M.A.; Siveke J.T.; Dollinger M.M.; Scheulen M.E.; Wege H.; Giannini E.G.; Cillo U.; Trevisani F.; Resminostat in advanced hepatocellular carcinoma (HCC): Overall survival subgroup analysis of prognostic factors in the shelter trial. J Clin Oncol 2013","journal-title":"J Clin Oncol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1021\/jm901453q","volume":"53","author":"Cai X.","year":"2010","unstructured":"Cai X.; Zhai H.X.; Wang J.; Forrester J.; Qu H.; Yin L.; Lai C.J.; Bao R.; Qian C.; Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem 2010,53(5),2000-2009","journal-title":"J Med Chem"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1158\/0008-5472.CAN-09-3360","volume":"70","author":"Lai C.J.","year":"2010","unstructured":"Lai C.J.; Bao R.; Tao X.; Wang J.; Atoyan R.; Qu H.; Wang D.G.; Yin L.; Samson M.; Forrester J.; Zifcak B.; Xu G.X.; DellaRocca S.; Zhai H.X.; Cai X.; Munger W.E.; Keegan M.; Pepicelli C.V.; Qian C.; CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res 2010,70(9),3647-3656","journal-title":"Cancer Res"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1158\/1535-7163.MCT-14-0220","volume":"13","author":"Dasmahapatra G.","year":"2014","unstructured":"Dasmahapatra G.; Patel H.; Friedberg J.; Quayle S.N.; Jones S.S.; Grant S.; In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells. Mol Cancer Ther 2014,13(12),2886-2897","journal-title":"Mol Cancer Ther"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1182\/blood.V124.21.3124.3124","volume":"21","author":"Cosenza M.","year":"2014","unstructured":"Cosenza M.; Civallero M.; Pozzi S.; Marcheselli L.; Sacchi S.; Preclinical screening of the HDAC6 inhibitor Rocilinostat (ACY-1215) combined with bendamustine in lymphoma cell lines. Blood 2014,21,3124","journal-title":"Blood"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/neuonc\/nor072","volume":"13","author":"Bush M.L.","year":"2011","unstructured":"Bush M.L.; Oblinger J.; Brendel V.; Santarelli G.; Huang J.; Akhmametyeva E.M.; Burns S.S.; Wheeler J.; Davis J.; Yates C.W.; Chaudhury A.R.; Kulp S.; Chen C.S.; Chang L.S.; Welling D.B.; Jacob A.; AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro-oncol 2011,13(9),983-999","journal-title":"Neuro-oncol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1158\/0008-5472.CAN-08-0203","volume":"68","author":"Sargeant A.M.","year":"2008","unstructured":"Sargeant A.M.; Rengel R-C.; Kulp S.K.; Klein R.D.; Clinton S.K.; Wang Y.C.; Chen C.S.; OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008,68(10),3999-4009","journal-title":"Cancer Res"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1021\/jm0503749","volume":"48","author":"Lu Q.","year":"2005","unstructured":"Lu Q.; Wang D.S.; Chen C-S.; Hu Y-D.; Chen C-S.; Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem 2005,48(17),5530-5535","journal-title":"J Med Chem"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-2141.2010.08126.x","volume":"149","author":"St\u00fchmer T.","year":"2010","unstructured":"St\u00fchmer T.; Arts J.; Chatterjee M.; Borawski J.; Wolff A.; King P.; Einsele H.; Leo E.; Bargou R.C.; Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585. Br J Haematol 2010,149(4),529-536","journal-title":"Br J Haematol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/pbc.24724","volume":"61","author":"Carol H.","year":"2014","unstructured":"Carol H.; Gorlick R.; Kolb E.A.; Morton, C.L.; Manesh, D.M.; Keir, S.T.; Reynolds, C.P.; Kang, M.H.; Maris, J.M.; Wozniak, A.; Hickson, H.; Lyalin, D.; Kurmasheva, R.T.; Houghton, P.J.; Smith, M.A.; Lock, R. Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the pediatric preclinical testing. Pediatr Blood Cancer 2014,61,245-252","journal-title":"Pediatr Blood Cancer"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"10842","DOI":"10.1021\/ja102758v","volume":"132","author":"Butler K.V.","year":"2010","unstructured":"Butler K.V.; Kalin J.; Brochier C.; Vistoli G.; Langley B.; Kozikowski A.P.; Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 2010,132(31),10842-10846","journal-title":"J Am Chem Soc"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"20003","DOI":"10.1073\/pnas.1013754107","volume":"107","author":"Namdar M.","year":"2010","unstructured":"Namdar M.; Perez G.; Ngo L.; Marks P.A.; Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci USA 2010,107(46),20003-20008","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1172\/JCI80713","volume":"125","author":"Nakashima H.","year":"2015","unstructured":"Nakashima H.; Kaufmann J.K.; Wang P.Y.; Nguyen T.; Speranza M.C.; Kasai K.; Okemoto K.; Otsuki A.; Nakano I.; Fernandez S.; Goins W.F.; Grandi P.; Glorioso J.C.; Lawler S.; Cripe T.P.; Chiocca E.A.; Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. J Clin Invest 2015,125(11),4269-4280","journal-title":"J Clin Invest"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3109\/10428194.2011.570821","volume":"8","author":"Aldana-Masangkay G.I.","year":"2011","unstructured":"Aldana-Masangkay G.I.; Rodriguez-Gonzalez A.; Lin T.; Ikeda, A.K.; Hsieh, Y.T.; Kim,Y.M.; Lome nick, B.; Okemoto, K.; Landaw, E.M.; Wang, D.; Mazitschek, R.; Bradner, J.E.; Sakamoto, K.M. Tubacin suppresses proli-feration and induces apoptosis of acute lymphoblastic leukemia cells. Leuk Lymphoma 2011,8,1544-1555","journal-title":"Leuk Lymphoma"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3389\/fneur.2015.00044","volume":"6","author":"Soragni E.","year":"2015","unstructured":"Soragni E.; Chou C.J.; Rusche J.R.; Gottesfeld J-M.; Mechanism of Action of 2-Aminobenzamide HDAC Inhibitors in Reversing Gene Silencing in Friedreich\u2019s Ataxia. Front Neurol 2015,6,44","journal-title":"Front Neurol"},{"key":"ref=141","first-page":"4459","volume":"61","author":"Komatsu Y.","year":"2001","unstructured":"Komatsu Y.; Tomizaki K.Y.; Tsukamoto M.; Kato T.; Nishino N.; Sato S.; Yamori T.; Tsuruo T.; Furumai R.; Yoshida M.; Horinouchi S.; Hayashi H.; Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res 2001,61(11),4459-4466","journal-title":"Cancer Res"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000292362","volume":"78","author":"Murakami K.","year":"2010","unstructured":"Murakami K.; Matsubara H.; Hoshino I.; Akutsu Y.; Miyazawa Y.; Matsushita K.; Sakata H.; Nishimori T.; Usui A.; Kano M.; Nishino N.; Yoshida M.; CHAP31 induces apoptosis only via the intrinsic pathway in human esophageal cancer cells. Oncology 2010,78(1),62-74","journal-title":"Oncology"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"6957","DOI":"10.1158\/0008-5472.CAN-05-0836","volume":"65","author":"Bevins R.L.","year":"2005","unstructured":"Bevins R.L.; Zimmer S.G.; It\u2019s about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res 2005,65(15),6957-6966","journal-title":"Cancer Res"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.bbamcr.2007.05.002","volume":"1773","author":"Donadelli M.","year":"2007","unstructured":"Donadelli M.; Costanzo C.; Beghelli S.; Scupoli M.T.; Dandrea M.; Bonora A.; Piacentini P.; Budillon A.; Caraglia M.; Scarpa A.; Palmieri M.; Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 2007,1773(7),1095-1106","journal-title":"Biochim Biophys Acta"},{"key":"ref=145","first-page":"971","volume":"2","author":"Fuino L.","year":"2003","unstructured":"Fuino L.; Bali P.; Wittmann S.; Donapaty S.; Guo F.; Yamaguchi H.; Wang H.G.; Atadja P.; Bhalla K.; Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2003,2(10),971-984","journal-title":"Mol Cancer Ther"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.3892\/ijo.2011.943","volume":"38","author":"Meli M.","year":"2011","unstructured":"Meli M.; Tolomeo M.; Grifantini M.; Mai A.; Cappellacci L.; Petrelli R.; Rotili D.; Ferro A.; Saiko P.; Szekeres T.; Dusonchet L.; Histone deacetylase inhibition modulates deoxyribonucleotide pools and enhances the antitumor effects of the ribonucleotide reductase inhibitor 3\u2032-C-methyladenosine in leukaemia cells. Int J Oncol 2011,38(5),1427-1436","journal-title":"Int J Oncol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1021\/jm048944c","volume":"48","author":"Franchetti P.","year":"2005","unstructured":"Franchetti P.; Cappellacci L.; Pasqualini M.; Petrelli R.; Vita P.; Jayaram H.N.; Horvath Z.; Szekeres T.; Grifantini M.; Antitumor activity of C-methyl-\u03b2-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors. J Med Chem 2005,48(15),4983-4989","journal-title":"J Med Chem"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1135\/cccc20061088","volume":"71","author":"Cappellacci L.","year":"2006","unstructured":"Cappellacci L.; Franchetti P.; Petrelli R.; Riccioni S.; Vita P.; Jayaram H.N.; Grifantini M.; Purine and pyrimidine nucleoside analogs of 3\u2032-C-methyladenosine as antitumor agents. Collect Czech Chem Commun 2006,71,1088-1098","journal-title":"Collect Czech Chem Commun"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2174\/1573406053765431","volume":"3","author":"Mai A.","year":"2005","unstructured":"Mai A.; Massa S.; Pezzi R.; Valente S.; Loidl P.; Brosch G.; Synthesis and biological evaluation of 2-, 3-, and 4-acylaminocinnamyl-N-hydroxyamides as novel synthetic HDAC inhibitors. J Med Chem 2005,3,245-254","journal-title":"J Med Chem"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"31","DOI":"10.18632\/oncotarget.430","volume":"3","author":"Stauber R.H.","year":"2012","unstructured":"Stauber R.H.; Knauer S.K.; Habtemichael N.; Bier C.; Unruhe B.; Weisheit S.; Spange S.; Nonnenmacher F.; Fetz V.; Ginter T.; Reichardt S.; Liebmann C.; Schneider G.; Kr\u00e4mer O.H.; A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. Oncotarget 2012,3(1),31-43","journal-title":"Oncotarget"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/j.1349-7006.2011.01921.x","volume":"102","author":"Sung V.","year":"2011","unstructured":"Sung V.; Richard N.; Brady H.; Maier A.; Kelter G.; Heise C.; Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells. Cancer Sci 2011,102(6),1201-1207","journal-title":"Cancer Sci"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1158\/1078-0432.CCR-11-3165","volume":"18","author":"Banerji U.","year":"2012","unstructured":"Banerji U.; van Doorn L.; Papadatos-Pastos D.; Kristeleit R.; Debnam P.; Tall M.; Stewart A.; Raynaud F.; Garrett M.D.; Toal M.; Hooftman L.; De Bono J.S.; Verweij J.; Eskens F.A.; A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res 2012,18(9),2687-2694","journal-title":"Clin Cancer Res"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00280-012-1847-5","volume":"69","author":"Dong M.","year":"2012","unstructured":"Dong M.; Ning Z-Q.; Xing P-Y.; Xu J-L.; Cao H.X.; Dou G.F.; Meng Z.Y.; Shi Y.K.; Lu X.P.; Feng F.Y.; Phase I study of chidamide (CS055\/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol 2012,69(6),1413-1422","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2147\/OTT.S93528","volume":"10","author":"Chan T.S.","year":"2017","unstructured":"Chan T.S.; Tse E.; Kwong Y.L.; Chidamide in the treatment of peripheral T-cell lymphoma. OncoTargets Ther 2017,10,347-352","journal-title":"OncoTargets Ther"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1073\/pnas.96.8.4592","volume":"6","author":"Saito A.","year":"1999","unstructured":"Saito A.; Yamashita T.; Mariko Y.; Nosaka, Y.; Tsuchiya, K.; Ando, T.; Suzuki, T.; Tsuruo, T.; Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-275, with marked in vivo antitumor activity against human umors. Proc Natl Acad Sci USA 1999,6,4592-4597","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/bjc.2011.527","volume":"106","author":"Pili R.","year":"2012","unstructured":"Pili R.; Salumbides B.; Zhao M.; Altiok S.; Qian D.; Zwiebel J.; Carducci M.A.; Rudek M.A.; Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 2012,106(1),77-84","journal-title":"Br J Cancer"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1756-8722-3-5","volume":"3","author":"Tan J.","year":"2010","unstructured":"Tan J.; Cang S.; Ma Y.; Petrillo R.L.; Liu D.; Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010,3,5","journal-title":"J Hematol Oncol"},{"key":"ref=158","first-page":"3637","volume":"63","author":"Rosato R.R.","year":"2003","unstructured":"Rosato R.R.; Almenara J.A.; Grant S.; The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1\/WAF1 1. Cancer Res 2003,63(13),3637-3645","journal-title":"Cancer Res"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/1535-7163.MCT-07-2026","volume":"7","author":"Fournel M.","year":"2008","unstructured":"Fournel M.; Bonfils C.; Hou Y.; Yan P.T.; Trachy-Bourget M.C.; Kalita A.; Liu J.; Lu A.H.; Zhou N.Z.; Robert M.F.; Gillespie J.; Wang J.J.; Ste-Croix H.; Rahil J.; Lefebvre S.; Moradei O.; Delorme D.; Macleod A.R.; Besterman J.M.; Li Z.; MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008,7(4),759-768","journal-title":"Mol Cancer Ther"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2007-10-115873","volume":"112","author":"Garcia-Manero G.","year":"2008","unstructured":"Garcia-Manero G.; Assouline S.; Cortes J.; Estrov Z.; Kantarjian H.; Yang H.; Newsome W.M.; Miller W.H.; Rousseau C.; Kalita A.; Bonfils C.; Dubay M.; Patterson T.A.; Li Z.; Besterman J.M.; Reid G.; Laille E.; Martell R.E.; Minden M.; Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008,112(4),981-989","journal-title":"Blood"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1365-2141.2009.07881.x","volume":"147","author":"Blum K.A.","year":"2009","unstructured":"Blum K.A.; Advani A.; Fernandez L.; Van Der Jagt R.; Brandwein J.; Kambhampati S.; Kassis J.; Davis M.; Bonfils C.; Dubay M.; Dumouchel J.; Drouin M.; Lucas D.M.; Martell R.E.; Byrd J.C.; Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 2009,147(4),507-514","journal-title":"Br J Haematol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/S1470-2045(11)70265-0","volume":"12","author":"Younes A.","year":"2011","unstructured":"Younes A.; Oki Y.; Bociek R.G.; Kuruvilla J.; Fanale M.; Neelapu S.; Copeland A.; Buglio D.; Galal A.; Besterman J.; Li Z.; Drouin M.; Patterson T.; Ward M.R.; Paulus J.K.; Ji Y.; Medeiros L.J.; Martell R.E.; Mocetinostat for relapsed classical Hodgkin\u2019s lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011,12(13),1222-1228","journal-title":"Lancet Oncol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1006489328324","volume":"19","author":"Prakash S.","year":"2001","unstructured":"Prakash S.; Foster B.J.; Meyer M.; Wozniak, A.; Heilbrun, L.K.; Flaherty, L.; Zalupski M.; Radulovic, L.; Valdivieso, M-; LoRusso, P.M. Chronic oral ad- ministration of CI-994: a phase I study. Invest New Drugs 2001,19,1-11","journal-title":"Invest New Drugs"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/leu.2013.231","volume":"28","author":"Minami J.","year":"2014","unstructured":"Minami J.; Suzuki R.; Mazitschek R.; Gorgun G.; Ghosh B.; Cirstea D.; Hu Y.; Mimura N.; Ohguchi H.; Cottini F.; Jakubikova J.; Munshi N.C.; Haggarty S.J.; Richardson P.G.; Hideshima T.; Anderson K.C.; Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia 2014,28(3),680-689","journal-title":"Leukemia"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"72","DOI":"10.7164\/antibiotics.56.72","volume":"56","author":"Mori H.","year":"2003","unstructured":"Mori H.; Urano Y.; Abe F.; Furukawa S.; Furukawa S.; Tsurumi Y.; Sakamoto K.; Hashimoto M.; Takase S.; Hino M.; Fujii T.; FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC). I. Taxonomy, fermentation, isolation and biological activities. J Antibiot (Tokyo) 2003,56(2),72-79","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/ja.2010.51","volume":"63","author":"Sasamura S.","year":"2010","unstructured":"Sasamura S.; Sakamoto K.; Takagaki S.; Yamada T.; Takase S.; Mori H.; Fujii T.; Hino M.; Hashimoto M.; AS1387392, a novel immunosuppressive cyclic tetrapeptide compound with inhibitory activity against mammalian histone deacetylase. J Antibiot (Tokyo) 2010,63(11),633-636","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/cmdc.200700095","volume":"2","author":"Gomez-Paloma L.","year":"2007","unstructured":"Gomez-Paloma L.; Bruno I.; Cini E.; Khochbin S.; Rodriquez M.; Taddei M.; Terracciano S.; Sadoul K.; Design and synthesis of cyclopeptide analogues of the potent histone deacetylase inhibitor FR235222. ChemMedChem 2007,2(10),1511-1519","journal-title":"ChemMedChem"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1158\/1078-0432.CCR-10-0738","volume":"17","author":"Su J.M.","year":"2011","unstructured":"Su J.M.; Li X.N.; Thompson P.; Ou C.N.; Ingle A.M.; Russell H.; Lau C.C.; Adamson P.C.; Blaney S.M.; Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children\u2019s oncology group report. Clin Cancer Res 2011,17(3),589-597","journal-title":"Clin Cancer Res"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1634\/theoncologist.2011-0031","volume":"16","author":"Mohammed T.A.","year":"2011","unstructured":"Mohammed T.A.; Holen K.D.; Jaskula-Sztul R.; Mulkerin D.; Lubner S.J.; Schelman W.R.; Eickhoff J.; Chen H.; Loconte N.K.; A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist 2011,16(6),835-843","journal-title":"Oncologist"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00280-014-2384-1","volume":"73","author":"Wheler J.J.","year":"2014","unstructured":"Wheler J.J.; Janku F.; Falchook G.S.; Jackson T.L.; Fu S.; Naing A.; Tsimberidou A.M.; Moulder S.L.; Hong D.S.; Yang H.; Piha-Paul S.A.; Atkins J.T.; Garcia-Manero G.; Kurzrock R.; Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol 2014,73(3),495-501","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=171","first-page":"5187","volume":"34","author":"Iwahashi S.","year":"2014","unstructured":"Iwahashi S.; Utsunomiya T.; Imura S.; Morine Y.; Ikemoto T.; Arakawa Y.; Saito Y.; Ishikawa D.; Shimada M.; Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I\/II. Anticancer Res 2014,34(9),5187-5191","journal-title":"Anticancer Res"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1590\/S1415-475738420150028","volume":"38","author":"Lee J.E.","year":"2015","unstructured":"Lee J.E.; Kim J.H.; Valproic acid inhibits the invasion of PC3 prostate cancer cells by upregulating the metastasis suppressor protein NDRG1. Genet Mol Biol 2015,38(4),527-533","journal-title":"Genet Mol Biol"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"5304","DOI":"10.1016\/j.bmcl.2014.09.046","volume":"24","author":"Petrelli R.","year":"2014","unstructured":"Petrelli R.; Meli M.; Vita P.; Torquati I.; Ferro A.; Vodnala M.; D\u2019Alessandro N.; Tolomeo M.; Del Bello F.; Kusumanchi P.; Franchetti P.; Grifantini M.; Jayaram H.N.; Hofer A.; Cappellacci L.; From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3\u2032-C-methyladenosine. Bioorg Med Chem Lett 2014,24(22),5304-5309","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2165\/11591280-000000000-00000","volume":"11","author":"Iannitti T.","year":"2011","unstructured":"Iannitti T.; Palmieri B.; Clinical and experimental applications of sodium phenylbutyrate. Drugs R D 2011,11(3),227-249","journal-title":"Drugs R D"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1196\/annals.1378.080","volume":"1091","author":"Merzvinskyte R.","year":"2006","unstructured":"Merzvinskyte R.; Treigyte G.; Savickiene J.; Magnusson K.E.; Navakauskiene R.; Effects of histone deacetylase inhibitors, sodium phenyl butyrate and vitamin B3, in combination with retinoic acid on granulocytic differentiation of human promyelocytic leukemia HL-60 cells. Ann N Y Acad Sci 2006,1091,356-367","journal-title":"Ann N Y Acad Sci"},{"key":"ref=176","first-page":"3047","volume":"7","author":"Carducci M.A.","year":"2001","unstructured":"Carducci M.A.; Gilbert J.; Bowling M.K.; Noe D.; Eisenberger M.A.; Sinibaldi V.; Zabelina Y.; Chen T.L.; Grochow L.B.; Donehower R.C.; A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 2001,7(10),3047-3055","journal-title":"Clin Cancer Res"},{"key":"ref=177","first-page":"681","volume":"6","author":"Witzig T.E.","year":"2000","unstructured":"Witzig T.E.; Timm M.; Stenson M.; Svingen P.A.; Kaufmann S.H.; Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin Cancer Res 2000,6(2),681-692","journal-title":"Clin Cancer Res"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00280-001-0390-6","volume":"49","author":"Feinman R.","year":"2002","unstructured":"Feinman R.; Clarke K.O.; Harrison L.E.; Phenylbutyrate-induced apoptosis is associated with inactivation of NF-kappaB IN HT-29 colon cancer cells. Cancer Chemother Pharmacol 2002,49(1),27-34","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=179","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1016\/S0021-9258(17)44885-X","volume":"265","author":"Yoshida M.","year":"1990","unstructured":"Yoshida M.; Kijima M.; Akita M.; Beppu T.; Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990,265(28),17174-17179","journal-title":"J Biol Chem"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nchembio.1223","volume":"9","author":"Lobera M.","year":"2013","unstructured":"Lobera M.; Madauss K.P.; Pohlhaus D.T.; Wright Q.G.; Trocha M.; Schmidt D.R.; Baloglu E.; Trump R.P.; Head M.S.; Hofmann G.A.; Murray-Thompson M.; Schwartz B.; Chakravorty S.; Wu Z.; Mander P.K.; Kruidenier L.; Reid R.A.; Burkhart W.; Turunen B.J.; Rong J.X.; Wagner C.; Moyer M.B.; Wells C.; Hong X.; Moore J.T.; Williams J.D.; Soler D.; Ghosh S.; Nolan M.A.; Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol 2013,9(5),319-325","journal-title":"Nat Chem Biol"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.3892\/ijo.2016.3402","volume":"48","author":"You B.R.","year":"2016","unstructured":"You B.R.; Park W.H.; The levels of HDAC1 and thioredoxin1 are related to the death of mesothelioma cells by suberoylanilide hydroxamic acid. Int J Oncol 2016,48(5),2197-2204","journal-title":"Int J Oncol"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cam4.939","volume":"6","author":"Foss F.","year":"2017","unstructured":"Foss F.; Pro B.; Miles Prince H.; Sokol L.; Caballero D.; Horwitz S.; Coiffier B.; Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Med 2017,6(1),36-44","journal-title":"Cancer Med"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1124\/jpet.102.042903","volume":"304","author":"De Schepper S.","year":"2003","unstructured":"De Schepper S.; Bruwiere H.; Verhulst T.; Steller U.; Andries L.; Wouters W.; Janicot M.; Arts J.; Van Heusden J.; Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin. J Pharmacol Exp Ther 2003,304(2),881-888","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1074\/jbc.M106699200","volume":"277","author":"Kwon S.H.","year":"2002","unstructured":"Kwon S.H.; Ahn S.H.; Kim Y.K.; Bae G.U.; Yoon J.W.; Hong S.; Lee H.Y.; Lee Y.W.; Lee H.W.; Han J.W.; Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas\/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 2002,277(3),2073-2080","journal-title":"J Biol Chem"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"7553","DOI":"10.1002\/anie.200602047","volume":"45","author":"Nakao Y.","year":"2006","unstructured":"Nakao Y.; Yoshida S.; Matsunaga S.; Shindoh N.; Terada Y.; Nagai K.; Yamashita J.K.; Ganesan A.; van Soest R.W.; Fusetani N.; Azumamides A-E: histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge Mycale izuensis. Angew Chem Int Ed Engl 2006,45(45),7553-7557","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"6512","DOI":"10.1021\/jm4008449","volume":"56","author":"Villadsen J.S.","year":"2013","unstructured":"Villadsen J.S.; Stephansen H.M.; Maolanon A.R.; Harris P.; Olsen C.A.; Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as \u03b2- epi-Azumamide E and \u03b2-epi-Azumamide E. J Med Chem 2013,56(16),6512-6520","journal-title":"J Med Chem"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1073\/pnas.98.1.87","volume":"98","author":"Furumai R.","year":"2001","unstructured":"Furumai R.; Komatsu Y.; Nishino N.; Khochbin S.; Yoshida M.; Horinouchi S.; Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA 2001,98(1),87-92","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ejca.2008.01.023","volume":"44","author":"Petrella A.","year":"2008","unstructured":"Petrella A.; D\u2019Acunto C.W.; Rodriquez M.; Festa M.; Tosco A.; Bruno I.; Terracciano S.; Taddei M.; Paloma L.G.; Parente L.; Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1. Eur J Cancer 2008,44(5),740-749","journal-title":"Eur J Cancer"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1021\/ja7110064","volume":"130","author":"Taori K.","year":"2008","unstructured":"Taori K.; Paul V.J.; Luesch H.; Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc 2008,130(6),1806-1807","journal-title":"J Am Chem Soc"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cbi.2014.07.004","volume":"221","author":"Rehman M.U.","year":"2014","unstructured":"Rehman M.U.; Jawaid P.; Yoshihisa Y.; Li P.; Zhao Q.L.; Narita K.; Katoh T.; Kondo T.; Shimizu T.; Spiruchostatin A and B, novel histone deacetylase inhibitors, induce apoptosis through reactive oxygen species-mitochondria pathway in human lymphoma U937 cells. Chem Biol Interact 2014,221,24-34","journal-title":"Chem Biol Interact"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jss.2014.02.042","volume":"190","author":"Weinlander E.","year":"2014","unstructured":"Weinlander E.; Somnay Y.; Harrison A.D.; Wang C.; Cheng Y.Q.; Jaskula-Sztul R.; Yu X.M.; Chen H.; The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth. J Surg Res 2014,190(1),191-197","journal-title":"J Surg Res"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/0196-9781(93)90160-I","volume":"14","author":"Bernardi E.","year":"1993","unstructured":"Bernardi E.; Fauchere J-L.; Atassi G.; Viallefont P.; Lazaro R.; Antitumoral cyclic peptide analogues of chlamydocin. Peptides 1993,14(6),1091-1093","journal-title":"Peptides"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1021\/acs.jmedchem.5b01632","volume":"59","author":"Reddy D.N.","year":"2016","unstructured":"Reddy D.N.; Ballante F.; Chuang T.; Pirolli A.; Marrocco B.; Marshall G.R.; Design and synthesis of simplified Largazole analogues as isoform-selective human lysine deacetylase inhibitors. J Med Chem 2016,59(4),1613-1633","journal-title":"J Med Chem"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1021\/ol070382e","volume":"9","author":"Fennell K.A.","year":"2007","unstructured":"Fennell K.A.; Miller M.J.; Syntheses of amamistatin fragments and determination of their HDAC and antitumor activity. Org Lett 2007,9(9),1683-1685","journal-title":"Org Lett"},{"key":"ref=195","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073097","volume":"8","author":"Venturelli S.","year":"2013","unstructured":"Venturelli S.; Berger A.; B\u00f6cker A.; Busch C.; Weiland T.; Noor S.; Leischner C.; Schleicher S.; Mayer M.; Weiss T.S.; Bischoff S.C.; Lauer U.M.; Bitzer M.; Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS One 2013,8(8)","journal-title":"PLoS One"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"R209","DOI":"10.1530\/ERC-13-0171","volume":"21","author":"Carter L.G.","year":"2014","unstructured":"Carter L.G.; D\u2019Orazio J.A.; Pearson K.J.; Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer 2014,21(3),R209-R225","journal-title":"Endocr Relat Cancer"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1089\/ars.2014.6097","volume":"22","author":"Tortorella S.M.","year":"2015","unstructured":"Tortorella S.M.; Royce S.G.; Licciardi P.V.; Karagiannis T.C.; Paul V.; Licciardi P.V.; Karagian C.; Dietary sulforaphane in cancer chemoprevention: the role of epigenetic regulation and HDAC inhibition. Antioxid Redox Signal 2015,22(16),1382-1424","journal-title":"Antioxid Redox Signal"},{"key":"ref=198","first-page":"5821","volume":"63","author":"Singh S.K.","year":"2003","unstructured":"Singh S.K.; Clarke I.D.; Terasaki M.; Bonn V.E.; Hawkins C.; Squire J.; Dirks P.B.; Identification of a cancer stem cell in human brain tumors. Cancer Res 2003,63(18),5821-5828","journal-title":"Cancer Res"},{"key":"ref=199","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/135039","volume":"2011","author":"Lorico A.","year":"2011","unstructured":"Lorico A.; Rappa G.; Phenotypic heterogeneity of breast cancer stem cells. J Oncol 2011,2011","journal-title":"J Oncol"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrd2137","volume":"8","author":"Zhou B.B.","year":"2009","unstructured":"Zhou B.B.; Zhang H.; Damelin M.; Geles K.G.; Grindley J.C.; Dirks P.B.; Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009,8(10),806-823","journal-title":"Nat Rev Drug Discov"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2217\/fon.13.108","volume":"9","author":"Li Y.","year":"2013","unstructured":"Li Y.; Zhang T.; Targeting cancer stem cells with sulforaphane, a dietary component from broccoli and broccoli sprouts. Future Oncol 2013,9(8),1097-1103","journal-title":"Future Oncol"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.canlet.2017.03.020","volume":"400","author":"Shahabipour F.","year":"2017","unstructured":"Shahabipour F.; Caraglia M.; Majeed M.; Derosa G.; Maffioli P.; Sahebkar A.; Naturally occurring anti-cancer agents targeting EZH2. Cancer Lett 2017,400,325-335","journal-title":"Cancer Lett"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1158\/1940-6207.CAPR-16-0044","volume":"9","author":"Saud S.M.","year":"2016","unstructured":"Saud S.M.; Li W.; Gray Z.; Matter M.S.; Colburn N.H.; Young M.R.; Kim Y.S.; Diallyl Disulfide (DADS), a Constituent of Garlic, Inactivates NF-\u03baB and Prevents Colitis-Induced Colorectal Cancer by Inhibiting GSK-3\u03b2. Cancer Prev Res (Phila) 2016,9(7),607-615","journal-title":"Cancer Prev Res (Phila)"},{"key":"ref=204","first-page":"219","volume":"26","author":"Yang J.S.","year":"2006","unstructured":"Yang J.S.; Kok L.F.; Lin Y.H.; Kuo T-C.; Yang J-L.; Lin C-C.; Chen G-W.; Huang W-W.; Ho H-C.; Chung J-G.; Diallyl disulfide inhibits WEHI-3 leukemia cells in vivo. Anticancer Res 2006,26(1A),219-225","journal-title":"Anticancer Res"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/j.1745-7270.2007.00356.x","volume":"39","author":"Huang Z.","year":"2007","unstructured":"Huang Z.; Lei X.; Zhong M.; Zhu B.; Tang S.; Liao D.; Bcl-2 small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549\/DDP cell to cisplatin and diallyl disulfide. Acta Biochim Biophys Sin (Shanghai) 2007,39(11),835-843","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3892\/or.19.1.275","volume":"19","author":"Jo H.J.","year":"2008","unstructured":"Jo H.J.; Song J.D.; Kim K.M.; Cho Y.H.; Kim K.H.; Park Y.C.; Diallyl disulfide induces reversible G2\/M phase arrest on a p53-independent mechanism in human colon cancer HCT-116 cells. Oncol Rep 2008,19(1),275-280","journal-title":"Oncol Rep"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1080\/01635581.2012.721156","volume":"64","author":"Altonsy M.O.","year":"2012","unstructured":"Altonsy M.O.; Habib T.N.; Andrews S.C.; Diallyl disulfide-induced apoptosis in a breast-cancer cell line (MCF-7) may be caused by inhibition of histone deacetylation. Nutr Cancer 2012,64(8),1251-1260","journal-title":"Nutr Cancer"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1016\/S0960-894X(02)00754-0","volume":"12","author":"Frey R.R.","year":"2002","unstructured":"Frey R.R.; Wada C.K.; Garland R.B.; Curtin M.L.; Michaelides M.R.; Li J.; Pease L.J.; Glaser K.B.; Marcotte P.A.; Bouska J.J.; Murphy S.S.; Davidsen S.K.; Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett 2002,12(23),3443-3447","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1016\/j.bmcl.2004.08.016","volume":"14","author":"Jose B.","year":"2004","unstructured":"Jose B.; Oniki Y.; Kato T.; Nishino N.; Sumida Y.; Yoshida M.; Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. Bioorg Med Chem Lett 2004,14(21),5343-5346","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/cmdc.201300433","volume":"9","author":"Madsen A.S.","year":"2014","unstructured":"Madsen A.S.; Kristensen H.M.; Lanz G.; Olsen C.A.; The effect of various zinc binding groups on inhibition of histone deacetylases 1-11. ChemMedChem 2014,9(3),614-626","journal-title":"ChemMedChem"},{"key":"ref=211","first-page":"4335","volume":"26","author":"Ideo A.","year":"2006","unstructured":"Ideo A.; Sasaki M.; Nakamura C.; Mori K.; Shimada J.; Kanda Y.; Kunii S.; Kawase M.; Sakagami H.; Cytotoxic activity of selected trifluoromethyl ketones against oral tumor cells. Anticancer Res 2006,26(6B),4335-4341","journal-title":"Anticancer Res"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2174\/138945012802008973","volume":"13","author":"Salvador L.A.","year":"2012","unstructured":"Salvador L.A.; Luesch H.; Discovery and mechanism of natural products as modulators of histone acetylation. Curr Drug Targets 2012,13(8),1029-1047","journal-title":"Curr Drug Targets"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1073\/pnas.95.7.3356","volume":"95","author":"Kwon H.J.","year":"1998","unstructured":"Kwon H.J.; Owa T.; Hassig C.A.; Shimada J.; Schreiber S.L.; Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc Natl Acad Sci USA 1998,95(7),3356-3361","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=214","doi-asserted-by":"crossref","first-page":"22429","DOI":"10.1016\/S0021-9258(18)41547-5","volume":"268","author":"Kijima M.","year":"1993","unstructured":"Kijima M.; Yoshida M.; Sugita K.; Horinouchi S.; Beppu T.; Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 1993,268(30),22429-22435","journal-title":"J Biol Chem"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1021\/np500387h","volume":"77","author":"Du L.","year":"2014","unstructured":"Du L.; Risinger A.L.; King J.B.; Powell D.R.; Cichewicz R.H.; A potent HDAC inhibitor, 1-alaninechlamydocin, from a Tolypocladium sp. induces G2\/M cell cycle arrest and apoptosis in MIA PaCa-2 cells. J Nat Prod 2014,77(7),1753-1757","journal-title":"J Nat Prod"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1039\/c2np00066k","volume":"29","author":"Hong J.","year":"2012","unstructured":"Hong J.; Luesch H.; Largazole: from discovery to broad-spectrum therapy. Nat Prod Rep 2012,29(4),449-456","journal-title":"Nat Prod Rep"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1021\/ml500170r","volume":"5","author":"Salvador L.A.","year":"2014","unstructured":"Salvador L.A.; Park H.; Al-Awadhi F.H.; Liu Y.; Kim B.; Zeller S.L.; Chen Q.Y.; Hong J.; Luesch H.; Modulation of activity profiles for largazole-based HDAC inhibitors through alteration of prodrug properties. ACS Med Chem Lett 2014,5(8),905-910","journal-title":"ACS Med Chem Lett"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1158\/1535-7163.MCT-07-2347","volume":"7","author":"Hassig C.A.","year":"2008","unstructured":"Hassig C.A.; Symons K.T.; Guo X.; Nguyen P.M.; Annable T.; Wash P.L.; Payne J.E.; Jenkins D.A.; Bonnefous C.; Trotter C.; Wang Y.; Anzola J.V.; Milkova E.L.; Hoffman T.Z.; Dozier S.J.; Wiley B.M.; Saven A.; Malecha J.W.; Davis R.L.; Muhammad J.; Shiau A.K.; Noble S.A.; Rao T.S.; Smith N.D.; Hager J.H.; KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008,7(5),1054-1065","journal-title":"Mol Cancer Ther"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"6093","DOI":"10.1016\/j.bmcl.2008.10.029","volume":"18","author":"Payne J.E.","year":"2008","unstructured":"Payne J.E.; Bonnefous C.; Hassig C.A.; Symons K.T.; Guo X.; Nguyen P.M.; Annable T.; Wash P.L.; Hoffman T.Z.; Rao T.S.; Shiau A.K.; Malecha J.W.; Noble S.A.; Hager J.H.; Smith N.D.; Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor. Bioorg Med Chem Lett 2008,18(23),6093-6096","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3762\/bjoc.9.11","volume":"9","author":"Baud M.G.","year":"2013","unstructured":"Baud M.G.; Leiser T.; Petrucci V.; Gunaratnam M.; Neidle S.; Meyer-Almes F.J.; Fuchter M.J.; Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors. Beilstein J Org Chem 2013,9,81-88","journal-title":"Beilstein J Org Chem"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1021\/jm0303094","volume":"46","author":"Miller T.A.","year":"2003","unstructured":"Miller T.A.; Witter D.J.; Belvedere S.; Histone deacetylase inhibitors. J Med Chem 2003,46(24),5097-5116","journal-title":"J Med Chem"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","volume":"33","author":"Zhang L.","year":"2018","unstructured":"Zhang L.; Zhang J.; Jiang Q.; Zhang L.; Song W.; Zinc binding groups for histone deacetylase inhibitors. J Enzyme Inhib Med Chem 2018,33(1),714-721","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1016\/j.bmcl.2010.03.091","volume":"20","author":"Bressi J.C.","year":"2010","unstructured":"Bressi J.C.; Jennings A.J.; Skene R.; Wu Y.; Melkus R.; De Jong R.; O\u2019Connell S.; Grimshaw C.E.; Navre M.; Gangloff A.R.; Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett 2010,20(10),3142-3145","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"26926","DOI":"10.1074\/jbc.M113.490706","volume":"288","author":"Lauffer B.E.","year":"2013","unstructured":"Lauffer B.E.; Mintzer R.; Fong R.; Mukund S.; Tam C.; Zilberleyb I.; Flicke B.; Ritscher A.; Fedorowicz G.; Vallero R.; Ortwine D.F.; Gunzner J.; Modrusan Z.; Neumann L.; Koth C.M.; Lupardus P.J.; Kaminker J.S.; Heise C.E.; Steiner P.; Structure of Human HDAC2 in complex with SAHA (vorinostat). J Biol Chem 2013,288,26926-26943","journal-title":"J Biol Chem"},{"key":"ref=225","first-page":"1165","volume":"13","author":"Haji Agha Bozorgi A.","year":"2014","unstructured":"Haji Agha Bozorgi A.; Zarghi A.; Search for the pharmacophore of histone deacetylase inhibitors using pharmacophore query and docking study. Iran J Pharm Res 2014,13(4),1165-1172","journal-title":"Iran J Pharm Res"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2174\/138161208783885335","volume":"14","author":"Itoh Y.","year":"2008","unstructured":"Itoh Y.; Suzuki T.; Miyata N.; Isoform-selective histone deacetylase inhibitors. Curr Pharm Des 2008,14(6),529-544","journal-title":"Curr Pharm Des"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1248\/cpb.57.897","volume":"57","author":"Suzuki T.","year":"2009","unstructured":"Suzuki T.; Explorative study on isoform-selective histone deacetylase inhibitors. Chem Pharm Bull (Tokyo) 2009,57(9),897-906","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/cmdc.201300413","volume":"9","author":"Thaler F.","year":"2014","unstructured":"Thaler F.; Mercurio C.; Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next. ChemMedChem 2014,9(3),523-526","journal-title":"ChemMedChem"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.4155\/fmc.13.141","volume":"5","author":"We\u00efwer M.","year":"2013","unstructured":"We\u00efwer M.; Lewis M.C.; Wagner F.F.; Holson E.B.; Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia. Future Med Chem 2013,5(13),1491-1508","journal-title":"Future Med Chem"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.2174\/1568026616666160212122609","volume":"16","author":"Ganai S.A.","year":"2016","unstructured":"Ganai S.A.; Novel approaches towards designing of isoform-selective inhibitors against class II histone deacetylases: The acute requirement for targeted anticancer therapy. Curr Top Med Chem 2016,16(22),2441-2452","journal-title":"Curr Top Med Chem"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2174\/1389450118666170112130151","volume":"19","author":"Ganai S.A.","year":"2018","unstructured":"Ganai S.A.; Designing isoform-selective inhibitors against classical HDACs for effective anticancer therapy: Insight and perspectives from in silico. Curr Drug Targets 2018,19(7),815-824","journal-title":"Curr Drug Targets"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1042\/BJ20070779","volume":"409","author":"Khan N.","year":"2008","unstructured":"Khan N.; Jeffers M.; Kumar S.; Hackett C.; Boldog F.; Khramtsov N.; Qian X.; Mills E.; Berghs S.C.; Carey N.; Finn P.W.; Collins L.S.; Tumber A.; Ritchie J.W.; Jensen P.B.; Lichenstein H.S.; Sehested M.; Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008,409(2),581-589","journal-title":"Biochem J"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2174\/1568026615666150813145629","volume":"16","author":"Ma N.","year":"2016","unstructured":"Ma N.; Luo Y.; Wang Y.; Liao C.; Ye W.C.; Jiang S.; Selective histone deacetylase inhibitors with anticancer activity. Curr Top Med Chem 2016,16(4),415-426","journal-title":"Curr Top Med Chem"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1039\/b703830p","volume":"37","author":"Bieliauskas A.V.","year":"2008","unstructured":"Bieliauskas A.V.; Pflum M.K.; Isoform-selective histone deacetylase inhibitors. Chem Soc Rev 2008,37(7),1402-1413","journal-title":"Chem Soc Rev"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.canlet.2009.02.013","volume":"280","author":"Balasubramanian S.","year":"2009","unstructured":"Balasubramanian S.; Verner E.; Buggy J.J.; Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 2009,280(2),211-221","journal-title":"Cancer Lett"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"7611","DOI":"10.1021\/acs.jmedchem.5b00229","volume":"58","author":"Zhan P.","year":"2015","unstructured":"Zhan P.; Itoh Y.; Suzuki T.; Liu X.; Strategies for the discovery of target-specific or isoform-selective modulators. J Med Chem 2015,58(19),7611-7633","journal-title":"J Med Chem"},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"7997","DOI":"10.1021\/jm401053m","volume":"56","author":"Day J.A.","year":"2013","unstructured":"Day J.A.; Cohen S.M.; Investigating the selectivity of metalloenzyme inhibitors. J Med Chem 2013,56(20),7997-8007","journal-title":"J Med Chem"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/cmdc.201500293","volume":"10","author":"Chen Y.","year":"2015","unstructured":"Chen Y.; Cohen S.M.; Investigating the selectivity of metalloenzyme inhibitors in the presence of competing metalloproteins. ChemMedChem 2015,10(10),1733-1738","journal-title":"ChemMedChem"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1021\/jm301355j","volume":"56","author":"Wagner F.F.","year":"2013","unstructured":"Wagner F.F.; Olson D.E.; Gale J.P.; Kaya T.; We\u00efwer M.; Aidoud N.; Thomas M.; Davoine E.L.; Lemercier B.C.; Zhang Y-L.; Holson E.B.; Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif. J Med Chem 2013,56(4),1772-1776","journal-title":"J Med Chem"},{"key":"ref=240","doi-asserted-by":"publisher","first-page":"7201","DOI":"10.1021\/jm400385r","volume":"56","author":"Blackburn C.","year":"2013","unstructured":"Blackburn C.; Barrett C.; Chin J.; Garcia K.; Gigstad K.; Gould A.; Gutierrez J.; Harrison S.; Hoar K.; Lynch C.; Rowland R.S.; Tsu C.; Ringeling J.; Xu H.; Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform. J Med Chem 2013,56(18),7201-7211","journal-title":"J Med Chem"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1021\/jm400390r","volume":"56","author":"Olson D.E.","year":"2013","unstructured":"Olson D.E.; Wagner F.F.; Kaya T.; Gale J.P.; Aidoud N.; Davoine E.L.; Lazzaro F.; We\u00efwer M.; Zhang Y-L.; Holson E.B.; Discovery of the first histone deacetylase 6\/8 dual inhibitors. J Med Chem 2013,56(11),4816-4820","journal-title":"J Med Chem"},{"key":"ref=242","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1021\/jm301254q","volume":"56","author":"Marek L.","year":"2013","unstructured":"Marek L.; Hamacher A.; Hansen F.K.; Kuna K.; Gohlke H.; Kassack M.U.; Kurz T.; Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem 2013,56(2),427-436","journal-title":"J Med Chem"},{"key":"ref=243","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1021\/acsmedchemlett.5b00302","volume":"7","author":"Luckhurst C.A.","year":"2015","unstructured":"Luckhurst C.A.; Breccia P.; Stott A.J.; Aziz O.; Birch H.L.; B\u00fcrli R.W.; Hughes S.J.; Jarvis R.E.; Lamers M.; Leonard P.M.; Matthews K.L.; McAllister G.; Pollack S.; Saville-Stones E.; Wishart G.; Yates D.; Dominguez C.; Potent, selective, and CNS-penetrant tetrasubstituted cyclopropane class IIa histone deacetylase (HDAC) inhibitors. ACS Med Chem Lett 2015,7(1),34-39","journal-title":"ACS Med Chem Lett"},{"key":"ref=244","doi-asserted-by":"publisher","first-page":"9934","DOI":"10.1021\/jm4011884","volume":"56","author":"B\u00fcrli R.W.","year":"2013","unstructured":"B\u00fcrli R.W.; Luckhurst C.A.; Aziz O.; Matthews K.L.; Yates D.; Lyons K.A.; Beconi M.; McAllister G.; Breccia P.; Stott A.J.; Penrose S.D.; Wall M.; Lamers M.; Leonard P.; M\u00fcller I.; Richardson C.M.; Jarvis R.; Stones L.; Hughes S.; Wishart G.; Haughan A.F.; O\u2019Connell C.; Mead T.; McNeil H.; Vann J.; Mangette J.; Maillard M.; Beaumont V.; Munoz-Sanjuan I.; Dominguez C.; Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington\u2019s disease. J Med Chem 2013,56(24),9934-9954","journal-title":"J Med Chem"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1007\/s00018-014-1656-6","volume":"71","author":"Zhang J.","year":"2014","unstructured":"Zhang J.; Zhong Q.; Histone deacetylase inhibitors and cell death. Cell Mol Life Sci 2014,71(20),3885-3901","journal-title":"Cell Mol Life Sci"},{"key":"ref=246","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.3390\/molecules20033898","volume":"20","author":"Mottamal M.","year":"2015","unstructured":"Mottamal M.; Zheng S.; Huang T.L.; Wang G.; Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 2015,20(3),3898-3941","journal-title":"Molecules"},{"key":"ref=247","doi-asserted-by":"publisher","first-page":"5950","DOI":"10.1016\/j.bmc.2010.06.081","volume":"18","author":"Chen L.","year":"2010","unstructured":"Chen L.; Petrelli R.; Gao G.; Wilson D.J.; McLean G.T.; Jayaram H.N.; Sham Y.Y.; Pankiewicz K.W.; Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylase based on a cinnamic hydroxamic acid core structure. Bioorg Med Chem 2010,18(16),5950-5964","journal-title":"Bioorg Med Chem"},{"key":"ref=248","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0092-8674(02)00625-6","volume":"108","author":"Johnstone R.W.","year":"2002","unstructured":"Johnstone R.W.; Ruefli A.A.; Lowe S.W.; Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002,108(2),153-164","journal-title":"Cell"},{"key":"ref=249","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"West A.C.","year":"2014","unstructured":"West A.C.; Johnstone R.W.; New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014,124(1),30-39","journal-title":"J Clin Invest"},{"key":"ref=250","first-page":"937","volume":"1","author":"Blagosklonny M.V.","year":"2002","unstructured":"Blagosklonny M.V.; Robey R.; Sackett D.L.; Du L.; Traganos F.; Darzynkiewicz Z.; Fojo T.; Bates S.E.; Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 2002,1(11),937-941","journal-title":"Mol Cancer Ther"},{"key":"ref=251","first-page":"733","volume":"6","author":"Zhang Z.","year":"2013","unstructured":"Zhang Z.; Hao C.; Wang L.; Liu P.; Zhao L.; Zhu C.; Tian X.; Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors. OncoTargets Ther 2013,6,733-740","journal-title":"OncoTargets Ther"},{"key":"ref=252","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4161\/cbt.3.5.985","volume":"3","author":"Zhang X.D.","year":"2004","unstructured":"Zhang X.D.; Gillespie S.K.; Borrow J.M.; Hersey P.; The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 2004,3(4),425-435","journal-title":"Mol Cancer Ther"},{"key":"ref=253","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053766","volume":"8","author":"Silva G.","year":"2013","unstructured":"Silva G.; Cardoso B.A.; Belo H.; Almeida A.M.; Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms. PLoS One 2013,8(1)","journal-title":"PLoS One"},{"key":"ref=254","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/86507","volume":"7","author":"Kim M.S.","year":"2001","unstructured":"Kim M.S.; Kwon H.J.; Lee Y.M.; Baek J.H.; Jang J.E.; Lee S.W.; Moon E.J.; Kim H.S.; Lee S.K.; Chung H.Y.; Kim C.W.; Kim K.W.; Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001,7(4),437-443","journal-title":"Nat Med"},{"key":"ref=255","doi-asserted-by":"publisher","first-page":"8814","DOI":"10.1158\/0008-5472.CAN-05-4598","volume":"66","author":"Qian D.Z.","year":"2006","unstructured":"Qian D.Z.; Kachhap S.K.; Collis S.J.; Verheul H.M.; Carducci M.A.; Atadja P.; Pili R.; Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 \u03b1. Cancer Res 2006,66(17),8814-8821","journal-title":"Cancer Res"},{"key":"ref=256","doi-asserted-by":"publisher","first-page":"14639","DOI":"10.1073\/pnas.1008522107","volume":"107","author":"Lee J.H.","year":"2010","unstructured":"Lee J.H.; Choy M.L.; Ngo L.; Foster S.S.; Marks P.A.; Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 2010,107(33),14639-14644","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=257","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1517\/14728222.9.4.809","volume":"9","author":"Rosato R.R.","year":"2005","unstructured":"Rosato R.R.; Grant S.; Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005,9(4),809-824","journal-title":"Expert Opin Ther Targets"},{"key":"ref=258","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.semcancer.2006.09.005","volume":"16","author":"Marks P.A.","year":"2006","unstructured":"Marks P.A.; Thioredoxin in cancer--role of histone deacetylase inhibitors. Semin Cancer Biol 2006,16(6),436-443","journal-title":"Semin Cancer Biol"},{"key":"ref=259","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1158\/1078-0432.CCR-04-2088","volume":"11","author":"Munshi A.","year":"2005","unstructured":"Munshi A.; Kurland J.F.; Nishikawa T.; Tanaka T.; Hobbs M.L.; Tucker S.L.; Ismail S.; Stevens C.; Meyn R.E.; Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 2005,11(13),4912-4922","journal-title":"Clin Cancer Res"},{"key":"ref=260","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.1158\/0008-5472.CAN-06-3996","volume":"67","author":"Chen C.S.","year":"2007","unstructured":"Chen C.S.; Wang Y.C.; Yang H.C.; Huang P.H.; Kulp S.K.; Yang C.C.; Lu Y.S.; Matsuyama S.; Chen C.Y.; Chen C.S.; Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 2007,67(11),5318-5327","journal-title":"Cancer Res"},{"key":"ref=261","doi-asserted-by":"publisher","first-page":"19482","DOI":"10.1073\/pnas.0707828104","volume":"104","author":"Adimoolam S.","year":"2007","unstructured":"Adimoolam S.; Sirisawad M.; Chen J.; Thiemann P.; Ford J.M.; Buggy J.J.; HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA 2007,104(49),19482-19487","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=262","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.5012\/bkcs.2012.33.6.2063","volume":"33","author":"Yang J.S.","year":"2012","unstructured":"Yang J.S.; Chun T-G.; Nam K-Y.; Kim H.M.; Han G.; Structure-activity relationship of novel lactam based histone deacetylase inhibitors as potential anticancer drugs. Bull Korean Chem Soc 2012,33,2063-2066","journal-title":"Bull Korean Chem Soc"},{"key":"ref=263","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.bmcl.2010.12.079","volume":"21","author":"Choi E.","year":"2011","unstructured":"Choi E.; Lee C.; Park J.E.; Seo J.J.; Cho M.; Kang J.S.; Kim H.M.; Park S.K.; Lee K.; Han G.; Structure and property based design, synthesis and biological evaluation of \u03b3-lactam based HDAC inhibitors. Bioorg Med Chem Lett 2011,21(4),1218-1221","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=264","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1016\/j.bmcl.2012.04.045","volume":"22","author":"Lee C.","year":"2012","unstructured":"Lee C.; Choi E.; Cho M.; Lee B.; Oh S.J.; Park S.K.; Lee K.; Kim H.M.; Han G.; Structure and property based design, synthesis and biological evaluation of \u03b3-lactam based HDAC inhibitors: part II. Bioorg Med Chem Lett 2012,22(12),4189-4192","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=265","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/med.20200","volume":"32","author":"Pontiki E.","year":"2012","unstructured":"Pontiki E.; Hadjipavlou-Litina D.; Histone deacetylase inhibitors (HDACIs). Structure--activity relationships: history and new QSAR perspectives. Med Res Rev 2012,32(1),1-165","journal-title":"Med Res Rev"},{"key":"ref=266","doi-asserted-by":"publisher","first-page":"9969","DOI":"10.1021\/jm401225q","volume":"56","author":"Sodji Q.H.","year":"2013","unstructured":"Sodji Q.H.; Patil V.; Kornacki J.R.; Mrksich M.; Oyelere A.K.; Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors. J Med Chem 2013,56(24),9969-9981","journal-title":"J Med Chem"},{"key":"ref=267","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.1016\/j.bmc.2008.03.050","volume":"16","author":"Chen P.C.","year":"2008","unstructured":"Chen P.C.; Patil V.; Guerrant W.; Green P.; Oyelere A.K.; Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group. Bioorg Med Chem 2008,16(9),4839-4853","journal-title":"Bioorg Med Chem"},{"key":"ref=268","doi-asserted-by":"publisher","first-page":"8635","DOI":"10.1016\/j.bmc.2008.08.003","volume":"16","author":"Di Micco S.","year":"2008","unstructured":"Di Micco S.; Terracciano S.; Bruno I.; Rodriquez M.; Riccio R.; Taddei M.; Bifulco G.; Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modeled on the natural product FR235222. Bioorg Med Chem 2008,16(18),8635-8642","journal-title":"Bioorg Med Chem"},{"key":"ref=269","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/cmdc.201300372","volume":"9","author":"Wang S.","year":"2014","unstructured":"Wang S.; Li X.; Wei Y.; Xiu Z.; Nishino N.; Discovery of potent HDAC inhibitors based on chlamydocin with inhibitory effects on cell migration. ChemMedChem 2014,9(3),627-637","journal-title":"ChemMedChem"},{"key":"ref=270","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1021\/jm2001025","volume":"54","author":"Neelarapu R.","year":"2011","unstructured":"Neelarapu R.; Holzle D.L.; Velaparthi S.; Bai H.; Brunsteiner M.; Blond S.Y.; Petukhov P.A.; Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes. J Med Chem 2011,54(13),4350-4364","journal-title":"J Med Chem"},{"key":"ref=271","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2174\/1386207319666160801154415","volume":"19","author":"Patel P.","year":"2016","unstructured":"Patel P.; Singh A.; Patel V.K.; Jain D.K.; Veerasamy R.; Rajak H.; Pharmacophore Based 3D-QSAR, Virtual Screening and docking studies on novel series of HDAC Inhibitors with thiophen linker as anticancer agents. Comb Chem High Throughput Screen 2016,19(9),735-751","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=272","first-page":"324","volume":"6","author":"Kandakatla N.","year":"2014","unstructured":"Kandakatla N.; Ramakrishnan G.; Molecular docking studies of designed benzamide derivatives as histone deacetylase 2 inhibitors. Int J Pharm Pharm Sci 2014,6,324-328","journal-title":"Int J Pharm Pharm Sci"},{"key":"ref=273","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/07391102.2012.10507409","volume":"29","author":"Thangapandian S.","year":"2012","unstructured":"Thangapandian S.; John S.; Lee K.W.; Molecular dynamics simulation study explaining inhibitor selectivity in different class of histone deacetylases. J Biomol Struct Dyn 2012,29(4),677-698","journal-title":"J Biomol Struct Dyn"},{"key":"ref=274","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049327","volume":"7","author":"Thangapandian S.","year":"2012","unstructured":"Thangapandian S.; John S.; Lee Y.; Arulalapperumal V.; Lee K.W.; Molecular modeling study on tunnel behavior in different histone deacetylase isoforms. PLoS One 2012,7(11)","journal-title":"PLoS One"},{"key":"ref=275","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00894-011-1240-z","volume":"18","author":"Berm\u00fadez-Lugo J.A.","year":"2012","unstructured":"Berm\u00fadez-Lugo J.A.; Perez-Gonzalez O.; Rosales-Hern\u00e1ndez M.C.; Ilizaliturri-Flores I.; Trujillo-Ferrara J.; Correa-Basurto J.; Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular dynamic simulations. J Mol Model 2012,18(6),2301-2310","journal-title":"J Mol Model"},{"key":"ref=276","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1016\/j.bmc.2010.03.080","volume":"18","author":"Estiu G.","year":"2010","unstructured":"Estiu G.; West N.; Mazitschek R.; Greenberg E.; Bradner J.E.; Wiest O.; On the inhibition of histone deacetylase 8. Bioorg Med Chem 2010,18(11),4103-4110","journal-title":"Bioorg Med Chem"},{"key":"ref=277","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1002\/jcc.23390","volume":"34","author":"Kalyaanamoorthy S.","year":"2013","unstructured":"Kalyaanamoorthy S.; Chen Y.P.; Ligand release mechanisms and channels in histone deacetylases. J Comput Chem 2013,34(26),2270-2283","journal-title":"J Comput Chem"},{"key":"ref=278","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.apsb.2011.10.002","volume":"1","author":"Lu H.","year":"2011","unstructured":"Lu H.; Chen Y-D.; Yang B.; You Q-D.; Design, synthesis and biological evaluation of novel histone deacetylase inhibitors based on virtual screening. Acta Pharm Sin B 2011,1,240-247","journal-title":"Acta Pharm Sin B"},{"key":"ref=279","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/cmdc.201100007","volume":"6","author":"Schlimme S.","year":"2011","unstructured":"Schlimme S.; Hauser A.T.; Carafa V.; Heinke R.R.; Kannan S.; Stolfa D.A.; Cellamare S.; Carotti A.; Altucci L.; Jung M.; Sippl W.; Carbamate prodrug concept for hydroxamate HDAC inhibitors. ChemMedChem 2011,6,1193-1198","journal-title":"ChemMedChem"},{"key":"ref=280","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00044-010-9519-7","volume":"21","author":"Zhang L.","year":"2012","unstructured":"Zhang L.; Li M.; Feng J.; Fang H.; Xu W.; Discovery of a novel histone deacetylase 8 inhibitor by virtual screening. Med Chem Res 2012,21,152-156","journal-title":"Med Chem Res"},{"key":"ref=281","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cmdc.200900500","volume":"5","author":"Park H.","year":"2010","unstructured":"Park H.; Kim S.; Kim Y.E.; Lim S.J.; A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups. ChemMedChem 2010,5(4),591-597","journal-title":"ChemMedChem"},{"key":"ref=282","first-page":"861","volume":"35","author":"Tatar B.","year":"2011","unstructured":"Tatar B.; Tokluman T.D.; Yelekci K.; Yurter H.; Power of inhibition activity screening and 3D molecular modeling approaches in HDAC 8 inhibitor design. Turk J Chem 2011,35,861-870","journal-title":"Turk J Chem"},{"key":"ref=283","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003645","volume":"9e","author":"Marek M.","year":"2013","unstructured":"Marek M.; Kannan S.; Hauser A.T.; Moraes Mourao M.; Caby S.; Cura V.; Stolfa D.A.; Schmidtkunz K.; Lancelot J.; Andrade L.; Renaud J.P.; Oliveira G.; Sippl W.; Jung M.; Cavarelli J.; Pierce R.J.; Romier C.; Structural basis for the player in the blood fluke schistosoma mansoni. PLoS Pathog 2013,9e","journal-title":"PLoS Pathog"},{"key":"ref=284","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1021\/ml300322n","volume":"4","author":"Zheng S.","year":"2013","unstructured":"Zheng S.; Zhong Q.; Jiang Q.; Mottamal M.; Zhang Q.; Zhu N.; Burow M.E.; Worthylake R.A.; Wang G.; Discovery of a series of thiazole derivatives as novel inhibitors of metastatic cancer cell migration and invasion. ACS Med Chem Lett 2013,4(2),191-196","journal-title":"ACS Med Chem Lett"},{"key":"ref=285","doi-asserted-by":"publisher","first-page":"6653","DOI":"10.1021\/jm500724x","volume":"57","author":"Zheng S.","year":"2014","unstructured":"Zheng S.; Zhong Q.; Xi Y.; Mottamal M.; Zhang Q.; Schroeder R.L.; Sridhar J.; He L.; McFerrin H.; Wang G.; Modification and biological evaluation of thiazole derivatives as novel inhibitors of metastatic cancer cell migration and invasion. J Med Chem 2014,57(15),6653-6667","journal-title":"J Med Chem"},{"key":"ref=286","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.bbapap.2012.08.009","volume":"1834","author":"Kalyaanamoorthy S.","year":"2013","unstructured":"Kalyaanamoorthy S.; Chen Y.P.; Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes. Biochim Biophys Acta 2013,1834(1),317-328","journal-title":"Biochim Biophys Acta"},{"key":"ref=287","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1080\/07391102.2013.879073","volume":"33","author":"Ganai S.A.","year":"2015","unstructured":"Ganai S.A.; Shanmugam K.; Mahadevan V.; Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms. J Biomol Struct Dyn 2015,33(2),374-387","journal-title":"J Biomol Struct Dyn"},{"key":"ref=288","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jmgm.2010.07.007","volume":"29","author":"Thangapandian S.","year":"2010","unstructured":"Thangapandian S.; John S.; Sakkiah S.; Lee K.W.; Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery. J Mol Graph Model 2010,29(3),382-395","journal-title":"J Mol Graph Model"},{"key":"ref=289","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1756-8722-2-31","volume":"2","author":"Siegel D.","year":"2009","unstructured":"Siegel D.; Hussein M.; Belani C.; Robert F.; Galanis E.; Richon V.M.; Garcia-Vargas J.; Sanz-Rodriguez C.; Rizvi S.; Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2009,2,31","journal-title":"J Hematol Oncol"},{"key":"ref=290","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/sj.bjc.6605293","volume":"101","author":"Munster P.N.","year":"2009","unstructured":"Munster P.N.; Marchion D.; Thomas S.; Egorin M.; Minton S.; Springett G.; Lee J-H.; Simon G.; Chiappori A.; Sullivan D.; Daud A.; Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 2009,101(7),1044-1050","journal-title":"Br J Cancer"},{"key":"ref=291","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1200\/JCO.2006.08.6165","volume":"25","author":"M\u00fcnster P.","year":"2007","unstructured":"M\u00fcnster P.; Marchion D.; Bicaku E.; Schmitt M.; Lee J.H.; DeConti R.; Simon G.; Fishman M.; Minton S.; Garrett C.; Chiappori A.; Lush R.; Sullivan D.; Daud A.; Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007,25(15),1979-1985","journal-title":"J Clin Oncol"},{"key":"ref=292","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1158\/1535-7163.MCT-08-0985","volume":"8","author":"Marchion D.C.","year":"2009","unstructured":"Marchion D.C.; Bicaku E.; Turner J.G.; Schmitt M.L.; Morelli D.R.; Munster P.N.; HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther 2009,8(4),794-801","journal-title":"Mol Cancer Ther"},{"key":"ref=293","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1158\/1535-7163.MCT-09-0038","volume":"8","author":"Baschnagel A.","year":"2009","unstructured":"Baschnagel A.; Russo A.; Burgan W.E.; Carter D.; Beam K.; Palmieri D.; Steeg P.S.; Tofilon P.; Camphausen K.; Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 2009,8(6),1589-1595","journal-title":"Mol Cancer Ther"},{"key":"ref=294","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3892\/ijo.2015.2996","volume":"47","author":"Groh T.","year":"2015","unstructured":"Groh T.; Hrabeta J.; Khalil M.A.; Doktorova H.; Eckschlager T.; Stiborova M.; The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells. Int J Oncol 2015,47(1),343-352","journal-title":"Int J Oncol"},{"key":"ref=295","doi-asserted-by":"publisher","first-page":"7138","DOI":"10.1158\/1078-0432.CCR-08-0122","volume":"14","author":"Luu T.H.","year":"2008","unstructured":"Luu T.H.; Morgan R.J.; Leong L.; Lim D.; McNamara M.; Portnow J.; Frankel P.; Smith D.D.; Doroshow J.H.; Wong C.; Aparicio A.; Gandara D.R.; Somlo G.; A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 2008,14(21),7138-7142","journal-title":"Clin Cancer Res"},{"key":"ref=296","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10549-006-9459-6","volume":"105","author":"Hodges-Gallagher L.","year":"2007","unstructured":"Hodges-Gallagher L.; Valentine C.D.; Bader S.E.; Kushner P.J.; Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat 2007,105(3),297-309","journal-title":"Breast Cancer Res Treat"},{"key":"ref=297","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1158\/0008-5472.CAN-04-2478","volume":"65","author":"Marchion D.C.","year":"2005","unstructured":"Marchion D.C.; Bicaku E.; Daud A.I.; Sullivan D.M.; Munster P.N.; Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 2005,65(9),3815-3822","journal-title":"Cancer Res"},{"key":"ref=298","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2217\/fon.11.2","volume":"7","author":"Thurn K.T.","year":"2011","unstructured":"Thurn K.T.; Thomas S.; Moore A.; Munster P.N.; Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011,7(2),263-283","journal-title":"Future Oncol"},{"key":"ref=299","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00280-010-1289-x","volume":"66","author":"Rathkopf D.","year":"2010","unstructured":"Rathkopf D.; Wong B.Y.; Ross R.W.; Anand A.; Tanaka E.; Woo M.M.; Hu J.; Dzik-Jurasz A.; Yang W.; Scher H.I.; A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2010,66(1),181-189","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=300","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/annonc\/mdp270","volume":"21","author":"Molife L.R.","year":"2010","unstructured":"Molife L.R.; Attard G.; Fong P.C.; Karavasilis V.; Reid A.H.M.; Patterson S.; Riggs C.E.; Higano C.; Stadler W.M.; McCulloch W.; Dearnaley D.; Parker C.; de Bono J.S.; Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol 2010,21(1),109-113","journal-title":"Ann Oncol"},{"key":"ref=301","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/pros.21187","volume":"70","author":"Pfeiffer M.J.","year":"2010","unstructured":"Pfeiffer M.J.; Mulders P.F.; Schalken J.A.; An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer. Prostate 2010,70(14),1524-1532","journal-title":"Prostate"},{"key":"ref=302","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/sj.bjc.6605726","volume":"103","author":"Lassen U.","year":"2010","unstructured":"Lassen U.; Molife L.R.; Sorensen M.; Engelholm S.A.; Vidal L.; Sinha R.; Penson R.T.; Buhl-Jensen P.; Crowley E.; Tjornelund J.; Knoblauch P.; de Bono J.S.; A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and\/or paclitaxel in patients with solid tumours. Br J Cancer 2010,103(1),12-17","journal-title":"Br J Cancer"},{"key":"ref=303","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrc2607","volume":"9","author":"Nitiss J.L.","year":"2009","unstructured":"Nitiss J.L.; Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009,9(5),338-350","journal-title":"Nat Rev Cancer"},{"key":"ref=304","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1021\/cr900097c","volume":"109","author":"Pommier Y.","year":"2009","unstructured":"Pommier Y.; DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 2009,109(7),2894-2902","journal-title":"Chem Rev"},{"key":"ref=305","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1158\/1535-7163.MCT-09-0254","volume":"8","author":"Bruzzese F.","year":"2009","unstructured":"Bruzzese F.; Rocco M.; Castelli S.; Di Gennaro E.; Desideri A.; Budillon A.; Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther 2009,8(11),3075-3087","journal-title":"Mol Cancer Ther"},{"key":"ref=306","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11060-010-0127-7","volume":"99","author":"Sarcar B.","year":"2010","unstructured":"Sarcar B.; Kahali S.; Chinnaiyan P.; Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines. J Neurooncol 2010,99(2),201-207","journal-title":"J Neurooncol"},{"key":"ref=307","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1007\/s10637-010-9467-6","volume":"29","author":"Budman D.R.","year":"2011","unstructured":"Budman D.R.; Tai J.; Calabro A.; John V.; The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines. Invest New Drugs 2011,29(6),1224-1229","journal-title":"Invest New Drugs"},{"key":"ref=308","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00428-006-0173-x","volume":"448","author":"Piacentini P.","year":"2006","unstructured":"Piacentini P.; Donadelli M.; Costanzo C.; Moore P.S.; Palmieri M.; Scarpa A.; Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 2006,448(6),797-804","journal-title":"Virchows Arch"},{"key":"ref=309","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1158\/1078-0432.CCR-08-1931","volume":"15","author":"Daud A.I.","year":"2009","unstructured":"Daud A.I.; Dawson J.; DeConti R.C.; Bicaku E.; Marchion D.; Bastien S.; Hausheer F.A.; Lush R.; Neuger A.; Sullivan D.M.; Munster P.N.; Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I\/II clinical trial. Clin Cancer Res 2009,15(7),2479-2487","journal-title":"Clin Cancer Res"},{"key":"ref=310","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1101\/gad.947102","volume":"16","author":"Bird A.","year":"2002","unstructured":"Bird A.; DNA methylation patterns and epigenetic memory. Genes Dev 2002,16(1),6-21","journal-title":"Genes Dev"},{"key":"ref=311","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"Kantarjian H.","year":"2006","unstructured":"Kantarjian H.; Issa J.P.; Rosenfeld C.S.; Bennett J.M.; Albitar M.; DiPersio J.; Klimek V.; Slack J.; de Castro C.; Ravandi F.; Helmer R.; Shen L.; Nimer S.D.; Leavitt R.; Raza A.; Saba H.; Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006,106(8),1794-1803","journal-title":"Cancer"},{"key":"ref=312","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"Silverman L.R.","year":"2002","unstructured":"Silverman L.R.; Demakos E.P.; Peterson B.L.; Kornblith A.B.; Holland J.C.; Odchimar-Reissig R.; Stone R.M.; Nelson D.; Powell B.L.; DeCastro C.M.; Ellerton J.; Larson R.A.; Schiffer C.A.; Holland J.F.; Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002,20(10),2429-2440","journal-title":"J Clin Oncol"},{"key":"ref=313","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/ajh.23464","volume":"88","author":"Ivanoff S.","year":"2013","unstructured":"Ivanoff S.; Gruson B.; Chantepie S.P.; Lemasle E.; Merlusca L.; Harrivel V.; Charbonnier A.; Votte P.; Royer B.; Marolleau J-P.; 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy. Am J Hematol 2013,88(7),601-605","journal-title":"Am J Hematol"},{"key":"ref=314","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1053\/j.seminhematol.2007.11.007","volume":"45","author":"Griffiths E.A.","year":"2008","unstructured":"Griffiths E.A.; Gore S.D.; DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 2008,45(1),23-30","journal-title":"Semin Hematol"},{"key":"ref=315","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/5047","volume":"21","author":"Cameron E.E.","year":"1999","unstructured":"Cameron E.E.; Bachman K.E.; My\u00f6h\u00e4nen S.; Herman J.G.; Baylin S.B.; Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999,21(1),103-107","journal-title":"Nat Genet"},{"key":"ref=316","first-page":"1596","volume":"9","author":"Segura-Pacheco B.","year":"2003","unstructured":"Segura-Pacheco B.; Trejo-Becerril C.; Perez-Cardenas E.; Taja-Chayeb L.; Mariscal I.; Chavez A.; Acu\u00f1a C.; Salazar A.M.; Lizano M.; Due\u00f1as-Gonzalez A.; Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 2003,9(5),1596-1603","journal-title":"Clin Cancer Res"},{"key":"ref=317","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000098","volume":"1","author":"Arce C.","year":"2006","unstructured":"Arce C.; P\u00e9rez-Plasencia C.; Gonz\u00e1lez-Fierro A.; de la Cruz-Hern\u00e1ndez E.; Revilla-V\u00e1zquez A.; Ch\u00e1vez-Blanco A.; Trejo-Becerril C.; P\u00e9rez-C\u00e1rdenas E.; Taja-Chayeb L.; Bargallo E.; Villarreal P.; Ram\u00edrez T.; Vela T.; Candelaria M.; Camargo M.F.; Robles E.; Due\u00f1as-Gonz\u00e1lez A.; A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One 2006,1","journal-title":"PLoS One"},{"key":"ref=318","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","volume":"18","author":"Candelaria M.","year":"2007","unstructured":"Candelaria M.; Gallardo-Rinc\u00f3n D.; Arce C.; Cetina L.; Aguilar-Ponce J.L.; Arrieta O.; Gonz\u00e1lez-Fierro A.; Ch\u00e1vez-Blanco A.; de la Cruz-Hern\u00e1ndez E.; Camargo M.F.; Trejo-Becerril C.; P\u00e9rez-C\u00e1rdenas E.; P\u00e9rez-Plasencia C.; Taja-Chayeb L.; Wegman-Ostrosky T.; Revilla-Vazquez A.; Due\u00f1as-Gonz\u00e1lez A.; A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007,18(9),1529-1538","journal-title":"Ann Oncol"},{"key":"ref=319","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/cncr.22087","volume":"107","author":"Kim H.","year":"2006","unstructured":"Kim H.; Kwon Y.M.; Kim J.S.; Han J.; Shim Y.M.; Park J.; Kim D-H.; Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 2006,107(5),1042-1049","journal-title":"Cancer"},{"key":"ref=320","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/j.1365-2559.2010.03494.x","volume":"56","author":"Barros F.F.","year":"2010","unstructured":"Barros F.F.; Powe D.G.; Ellis I.O.; Green A.R.; Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology 2010,56(5),560-572","journal-title":"Histopathology"},{"key":"ref=321","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000279388","volume":"77","author":"Lurje G.","year":"2009","unstructured":"Lurje G.; Lenz H.J.; EGFR signaling and drug discovery. Oncology 2009,77(6),400-410","journal-title":"Oncology"},{"key":"ref=322","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1158\/0008-5472.CAN-06-4397","volume":"67","author":"Harms K.L.","year":"2007","unstructured":"Harms K.L.; Chen X.; Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 2007,67(7),3145-3152","journal-title":"Cancer Res"},{"key":"ref=323","doi-asserted-by":"publisher","first-page":"16934","DOI":"10.1074\/jbc.M500403200","volume":"280","author":"Fu M.","year":"2005","unstructured":"Fu M.; Rao M.; Bouras T.; Wang C.; Wu K.; Zhang X.; Li Z.; Yao T-P.; Pestell R.G.; Cyclin D1 inhibits peroxisome proliferator-activated receptor \u03b3-mediated adipogenesis through histone deacetylase recruitment. J Biol Chem 2005,280(17),16934-16941","journal-title":"J Biol Chem"},{"key":"ref=324","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2174\/187152061405140501101624","volume":"14","author":"Passaro A.","year":"2014","unstructured":"Passaro A.; Alesini D.; Pochesci A.; Cortesi E.; Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer. Anticancer Agents Med Chem 2014,14(5),646-650","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=325","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1200\/JCO.2015.63.4154","volume":"34","author":"Urata Y.","year":"2016","unstructured":"Urata Y.; Katakami N.; Morita S.; Kaji R.; Yoshioka H.; Seto T.; Satouchi M.; Iwamoto Y.; Kanehara M.; Fujimoto D.; Ikeda N.; Murakami H.; Daga H.; Oguri T.; Goto I.; Imamura F.; Sugawara S.; Saka H.; Nogami N.; Negoro S.; Nakagawa K.; Nakanishi Y.; Randomized phase III study comparing Gefitinib with Erlotinib in patients with previously treated advanced lung Adenocarcinoma: WJOG 5108L. J Clin Oncol 2016,34(27),3248-3257","journal-title":"J Clin Oncol"},{"key":"ref=326","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.3390\/ph3092751","volume":"3","author":"Subramanian S.","year":"2010","unstructured":"Subramanian S.; Bates S.E.; Wright J.J.; Espinoza-Delgado I.; Piekarz R.L.; Piekarz R.L.; Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals (Basel) 2010,3(9),2751-2767","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=327","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/annonc\/mdn703","volume":"20","author":"Witta S.E.","year":"2009","unstructured":"Witta S.E.; Dziadziuszko R.; Yoshida K.; Hedman K.; Varella-Garcia M.; Bunn P.A.; Hirsch F.R.; Varella-Garcia M.; Bunn P.A.; Hirsch F.R.; ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). Ann Oncol 2009,20(4),689-695","journal-title":"Ann Oncol"},{"key":"ref=328","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/0008-5472.CAN-05-1988","volume":"66","author":"Witta S.E.","year":"2006","unstructured":"Witta S.E.; Gemmill R.M.; Hirsch F.R.; Coldren C.D.; Hedman K.; Ravdel L.; Helfrich B.; Dziadziuszko R.; Chan D.C.; Sugita M.; Chan Z.; Baron A.; Franklin W.; Drabkin H.A.; Girard L.; Gazdar A.F.; Minna J.D.; Bunn P.A.; Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006,66(2),944-950","journal-title":"Cancer Res"},{"key":"ref=329","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.3748\/wjg.v13.i33.4458","volume":"13","author":"Baradari V.","year":"2007","unstructured":"Baradari V.; H\u00f6pfner M.; Huether A.; Schuppan D.; Scher\u00fcbl H.; Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol 2007,13(33),4458-4466","journal-title":"World J Gastroenterol"},{"key":"ref=330","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1158\/1078-0432.CCR-08-0469","volume":"14","author":"Zhang G.","year":"2008","unstructured":"Zhang G.; Park M.A.; Mitchell C.; Hamed H.; Rahmani M.; Martin A.P.; Curiel D.T.; Yacoub A.; Graf M.; Lee R.; Roberts J.D.; Fisher P.B.; Grant S.; Dent P.; Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res 2008,14(17),5385-5399","journal-title":"Clin Cancer Res"},{"key":"ref=331","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood-2010-11-318055","volume":"117","author":"Bishton M.J.","year":"2011","unstructured":"Bishton M.J.; Harrison S.J.; Martin B.P.; McLaughlin N.; James C.; Josefsson E.C.; Henley K.J.; Kile B.T.; Prince H.M.; Johnstone R.W.; Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 2011,117(13),3658-3668","journal-title":"Blood"},{"key":"ref=332","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00277-009-0793-8","volume":"89","author":"Galli M.","year":"2010","unstructured":"Galli M.; Salmoiraghi S.; Golay J.; Gozzini A.; Crippa C.; Pescosta N.; Rambaldi A.; A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol 2010,89(2),185-190","journal-title":"Ann Hematol"},{"key":"ref=333","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/cmdc.201500486","volume":"11","author":"Shen S.","year":"2016","unstructured":"Shen S.; Kozikowski A.P.; Why hydroxamates may not be the best histone deacetylase inhibitors-what some may have forgotten or would rather forget? ChemMedChem 2016,11(1),15-21","journal-title":"ChemMedChem"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/166321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T01:32:23Z","timestamp":1662255143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/166321\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":333,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020,6,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867325666181016163110","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}